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1.  INTRODUCTION 
1.1 Cell respiration 
Cell respiration is the principal metabolic pathway by which eukaryotic and 
prokaryotic cells, in the presence of oxygen produce energy for their needs. It 
consists of a series of redox (reduction-oxidation) reactions, called oxidative 
phosphorilation (OXPHOS), during which substrates, such as glucose, are 
converted into H2O and CO2. The energy is stored in the form of ATP, a molecule 
discovered in 1899 by Karl Lohmann and whose central role in bioenergetics was 
defined by Fritz Lipmann in 1941. ATP carries chemical energy to be used by all 
the energy-consuming cell functions, including protein biosynthesis, locomotion 
or transportation of molecules across cell membrane and compartments. Not only 
OXPHOS, but also glycolysis is set to produce ATP in the cells, particularly 
under low O2 tension. Interestingly, most cancer cell types, despite their 
apparently intact mitochondria and a virtually efficient OXPHOS, commonly 
switch from OXPHOS to the energetically less favorable glycolysis in a metabolic 
transition termed the Warburg effect and the condition facilitaties a shift to 
anabolic pathways [1]. In eukaryotes, glycolysis occurs in the cell cytoplasm 
whereas both OXPHOS and the Krebs cycle occur in the mitochondrion, in the 
inner mitochondrial membrane and in the mitochondrial matrix, respectively. 
Mitochondria are the central organelles in a variety of essential cell functions and 
have been, therefore, the focus of numerous studies for many years. Mitochondria 
are membrane-enclosed organelles distributed in the cytosol of most eukaryotic 
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cells. Mitochondria are typically 0.7 - 1 µm in length. The number of 
mitochondria in a cell varies widely within organisms and tissue types. 
Mitochondria are compartmentalized by two membranes, made of phospholipids 
and containing highly specialized proteins. The outer membrane bilayer encloses 
the entire organelle and is freely permeable to ions and most small metabolites. 
The inner mitochondrial membrane is assembled in many folds called “cristae”, 
which expand the surface area of the membrane. The inner membrane is highly 
impermeable to all molecules and most ions, which require specific membrane 
transporters to enter or exit the matrix. The protein-mediated and -regulated 
permeability of the inner membrane is of vital importance for the morphological 
and functional integrity of the mitochondrion. As mentioned before, the oxidative 
phosphorylation occurs at the level of the inner mitochondrial membrane while 
the citric acid cycle and the oxidation of fatty acids, i.e. the main sources of 
NADH and FADH2, occur in the matrix. NADH or FADH2 convey electrons to 
the electron transport respiratory system. The system contains membrane-bound 
electron carriers that are organized in the so called respiratory chain. The 
NADH:ubiquinone oxidoreductase (also called NADH dehydrogenase) is the 
mitochondrial Complex I and catalyzes the first step of oxidative phosphorylation, 
through the transfer of two electrons from NADH to a lipid-soluble 
carrier, ubiquinone (Q). The succinate dehydrogenase is Complex II and may 
directly catalyze the reduction of quinone. The ubiquinol-cytochrome c 
oxidoreductase is complex III and oxidizes ubiquinol while reducing cytochrome 
c (cyt c). The cytochrome c oxidase (CcOX), complex IV, carries electrons from 
cyt c to molecular oxygen that is reduced to water using up protons in the matrix 
(scalar protons). The ATP synthase (Complex V) catalyzes the synthesis of ATP. 
Ubiquinone and cyt c are freely-diffusible molecules that shuttles electrons from 
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one complex to the next one, according to their redox potential. At the level of 
complex I, III and IV, the free energy released is used to traslocate protons (H+) 
from the mitochondrial matrix into the intermembrane space (vectorial proton 
pumping). Both vectorial and scalar reactions generate a proton electrochemical 
potential gradient across the inner mitochondrial membrane (∆µH+), the so called 
proton–motive force. ∆µH+ is used to drive endoergonic reactions; among them, 
the synthesis of ATP by ATP synthase is, indeed, the main responsible reaction 
for the back flux of protons into the matrix and the gradient dissipation. The 
proton motive force has two components: i) the trasmembrane electrical potential 
(∆ψ), which arises from the net accumulation of positive charges (H+) in the 
intermembrane space, while under standard matrix bears a net negative charge and 
ii) the trasmembrane pH gradient (∆pH). The relationship between these two 
components is expressed by the Mitchell equation: 
∆µH+ = ∆Ψ - 60 ∆pH 
Cytochome c oxidase contributes to the energyzation of the inner mitochondrial 
membrane, by reduction of O2 to H2O and by the proton-pumping out of the 
mitochondrial matrix.  
1.1.1 Cytochrome c oxidase 
Cytochrome c oxidase (CcOX) (EC 1.9.3.1) is a complex metalloprotein located 
in the inner mitochondrial membrane. The enzyme catalyzes the oxidation of 
cytochrome c and reduction of oxygen to water. CcOX is a member of the 
superfamily of heam-copper oxidases. The 3D crystallographic structure of 
several heme-copper oxidases has been solved since 1995 (see Fig. 1) [2-4]. The 
mammalian purified CcOx is a dimer where each monomer is 204.5 kDa. The 
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enzyme is formed by 3-4 subunits in prokaryotes, in eukaryotes by 13 subunits; of 
these, subunit I, II and III are forming the core of the enzyme and are coded by 
mitochondrial genes; these subunits are very similar to the corresponding subunits 
in Paracoccus Denitrificans. 
 
 
 
Fig. 1: a) Structure of the CcOX from beef heart. b) Oxidized active site of the beef heart enzyme 
(modified from Tsukihara et al, 1995; Tsukihara et al, 1996).  
 
The subunit I, tightly in contact with subunit II and III, is made by 12 
transmembrane helices and contains 3 of the 4 redox centres of the enzyme, 
namely haem a, a3 and CuB. The subunit II is constituted by 2 hydrophilic 
transmembrane helices and one hydrophilic domain protruding in the cytosolic 
side of the mitochondrial membrane, and containing the bimetallic site CuA. The 
subunit III is constituted by 7 transmembrane helices involved in the control of 
the proton pumping activity [5]. It presents a large cavity in which two molecules 
of lipids (phosphatidylethanolamine and phosphatidylglycerol) have been 
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detected. The enzyme contains 4 redox-active metal sites: CuA (two coppers 
organised in a single site), haem a, haem a3 and CuB. The enzyme contains also 
redox inactive metals such as Mg2+ and Zn2+ playing most probably a structural 
role. The bimetallic site CuA, presents a tetrahedric structure in which two Cu 
(copper-copper dimer) are bound by the sulfhur of Cys196
 
and Cys200
, 
like a centre 
(2Fe-2S). Haem a is a low-spin haem with two histidine (His61, His378) residues as 
axial Fe-ligands. It transfers electrons from CuA to the binuclear centre. The 
binuclear centre is formed by the high spin haem a3 and the copper ion (CuB). It is 
the catalytic centre for O2 reduction. The haem a3 appears to be penta-coordinated 
and
 
its ligand is the His376. CuB is coordinated by His
290
,
 
His291
 
and His240, the 
latter is covalently linked to the highly conserved tyrosine Tyr244; this tyrosine has 
a radical character in one of the catalytic intermediates, possibly playing a crucial 
role in catalysis. The bimetallic active site (haem a3-CuB) of CcOX, O2 is reduced 
to H2O and all CcOX ligands, such as NO, CO and CN
-
, bind.  
In the O2 reduction to water, 4 electrons are transferred to CcOX from cytochrome 
c following this pathway:  
 
cyt c → CuA → cyt a → cyt a3-CuB → O2 
 
The binuclear haem a3
_CuB centre is reduced by the electrons donated by 
cytochrome c and arriving intramolecularly via CuA and haem a; after complete 
reduction the binuclear site is oxidized by oxygen completing the reaction cycle. 
Also for the sake of identifying the intermediates relevant in the nitric oxide 
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binding chemistry, the catalytic cycle can be divided into a reductive and an 
oxidative part as shown in the scheme:  
 
 
 
In the reductive part the oxidized active site O (haem a3-CuB), accepts two 
electrons sequentially from CuA via cytochrome a. This is an intra-molecular 
electron transfer that yields the fully two-electrons reduced site R, via a single-
electron reduced intermediate E in which the electron can reside either on haem a3 
(species E1) or on CuB (species E2) [6]. The rate-limiting step of the catalytic 
cycle is the intramolecular reduction of the binuclear site. In the much faster 
oxidative part (µs vs ms), upon reaction with O2, R restores the fully oxidized 
enzyme O, by populating the O2 intermediates P and F [7]. Interestingly and at 
substantial variance with O2, NO proved able to react with all intermediate CcOX 
species [8].  
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1.1.2 Mitochondrial nitro-oxidative stress 
Mitochondrial respiration is the most important energy product process, but it is 
also recognized as the most relevant source of reactive oxygen and nitrogen 
species (RONS) in the majority of eukaryotic cell types [9]. RONS are small 
molecules which are highly reactive due to their unpaired valence shell electrons; 
average life-time values are 10-6, 10-5, 10-9 seconds for singlet oxygen, superoxide 
radical and hydroxyl radical, respectively (Fig. 2). In response to a variety of 
stressors, RONS production increases. When this occurs in conjunction with a 
limited antioxidant defense availability, a nitro-oxidative stress occurs, such a 
condition may ultimately lead to oxidative damage of cellular components, DNA, 
proteins and lipids. Despite their dark side, RONS are involved in the regulation 
of vital processes such as cellular signaling, the activation of cellular antioxidant 
defence system, the immune response, apoptosis and gene transcription, all 
functions serving several key roles in human physiology. Due to the high RONS 
reactivity, under optimal conditions, cells possess various molecular mechanism 
responsible for their control: these consist of both non-enzymatic and enzymatic 
systems. Non-enzymatic systems include hydrophylic and lipophylic radical 
scavengers, such as glutathione, cytochrome c (cyt-c), ascorbic acid, reduced 
coenzyme Q10, vitamin E, vitamin C and melatonin. Enzymatic components 
include manganese superoxide dismutase (Mn-SOD), catalase (CAT), glutathione 
peroxidase (GPx), glutaredoxin reductases (Grd) and peroxiredoxin. The 
regeneration of glutathione by glutathione reductase and reduced thioredoxin  by 
thioredoxin reductase depends on NADPH. Gene-mutations involving these 
enzymes, mutations in their corresponding genes have been associated with 
idiopathic cardiomyopathy, neurological sufferance, impairment glucose 
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metabolism, and cancer, all pathological states invariably displaying increased 
RONS level. In structurally and functionally intact  cells and mitochondria, 
antioxidant defense capacity balances RONS generation, limiting RONS 
bioavailability. 
  
 
 
Fig. 2: RONS (modified from Barzilai et al., 2002). 
 
Decreased antioxidant defense capacity is a prerequisite for increased net RONS 
production and nitro-oxidative stress. The primary RONS generated by 
mitochondria is superoxide anions (O2−). Formation of O2− in the mitochondrion 
occurs at the level of complex I and complex III. O2− is converted in the more 
stable, still highly reactive, H2O2 in mitochondria through the activity of matrix 
Mn-SOD and  in the intermembrane through the activity of Cu,Zn-SOD [10, 11]. 
H2O2 generated in mitochondria has a number of fates. Because H2O2 is relatively 
stable and membrane-permeable (transported by the aquaporins located in the 
inner mitochondrial membrane [12]), it can diffuse within the cell where it is 
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removed by cytosolic antioxidant systems such as catalase, glutathione peroxidase 
and thioredoxin peroxidase [13]. Mitochondrially generated H2O2 can also act as a 
signaling molecule in the cytosol, affecting multiple networks that control, for 
example, cell cycle, stress response, energy metabolism, and redox balance [14]. 
If not metabolized by the mitochondrial antioxidant systems, H2O2 is promptly 
decomposed via the Fenton reaction forming hydroxyl radicals. The hydroxyl 
radical is a potent reactive species, able to oxidize important targets, including 
nucleic acids, amino acids (tyrosine, phenylalanine, histidine), sugars and lipids 
[15]. Due to the high risk bound to the Fenton chemistry, it is feasible that 
mitochondria have developed both  an efficient H2O2 and metal-chelating removal 
systems. Experiments carried out using iron chelators proved their efficiency to 
prevent mitochondrial damage and loss of integrity due to enhanced ROS 
generation [16, 17].  
Mitochondria have also been credited as a source of reactive nitrogen species 
derived from nitric oxide (NO). The mitochondrial role of NO and its putative 
physiological signaling function will be extensively analyzed in the next chapter.  
Here it is important to underline that the intracellular redox state, might favor to a 
different extent the formation of peroxynitrite (ONOO–) using superoxide anions 
and NO. In turn, peroxynitrite nitrates and inhibits Mn-SOD, thereby preventing 
the breakdown of locally produced superoxide, which further fuels the formation 
of peroxynitrite [18].  
ONOO– exerts its harmful effects directly and indirectly (Fig. 3). ONOO– causes 
activation of transcriptional factors, including nuclear factor kappa B (NF-kB) and 
activator protein-1 (AP-1) leading to pro-inflammatory gene expression, including 
tumor necrosis factor a (TNF-α) and interleukin 1 (IL-1) [19]. Peroxynitrite can 
react with CO2, giving rise to CO3- and NO2- radicals. ONOO– directly interacts 
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with and covalently modifies all major types of biomolecules including membrane 
lipids, thiols, proteins, and DNA [15, 19]. Using both cultured cells and isolated 
submitochondrial fractions, peroxynitrite has been shown to exert significant 
inhibition to most components of the electron transport chain, through 
mechanisms involving, to various extents, cysteine oxidation, tyrosine nitration, 
and damage of iron sulfur centers. 
 
 
 
Fig. 3: Effects of ONOO– (modified from Korkmaz et al., 2009).  
 
A major protein target for nitrosation and nitration is respiratory Complex I [20]. 
ONOO– activates matrix metallo proteinases (MMPs) and inactivates several 
enzymes that are critically involved in the repair of DNA damage. Another target 
of peroxynitrite is cytochrome c, the nitration of which significantly impairs its 
redox properties [21, 22]. Notably, cytochrome c nitration increases its 
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peroxidatic activity, leading to the generation of hydrogen peroxide and 
exacerbation of oxidative damage to mitochondrial proteins. ONOO– further 
impairs energy metabolism by inhibiting the tricarboxylic acid cycle enzyme 
aconitase, as well as the mitochondrial creatine kinase, which is present in the 
intermembrane space. Nicotinamide nucleotide transhydrogenase, which allows 
formation of NADPH from NADH and NADP+, is another important 
mitochondrial protein oxidized, nitrated, and inactivated by peroxynitrite. The 
ensuing depletion of NADPH reduces the mitochondrial ability to regenerate 
GSH, contributing to the amplification of oxidative stress within the organelle. 
ONOO– induces cell apoptosis but also necrosis of cells. When the exposure to 
this agent persists, the activation of the DNA repair enzyme poly (ADP ribose) 
polymearase-1 (PARP-1) also occurred [23].  
Mitochondrial bioenergetics and redox state are also dependent on intracellular 
Ca2+ levels. Mitochondria are endowed with Ca2+ uniporters capable of rapidly 
promoting ∆Ψ-driven Ca2+ uptake into the matrix, most notably when Ca2+ is 
released by the endoplasmic reticulum [24]. Ca2+ can be accumulated in vast 
quantities in mitochondria, by mean of mitochondrial Ca2+ transporters despite 
their affinity for Ca2+ is lower than that the reticulum and plasma membrane 
transporters. Consistently, an elevated Ca2+ accumulation has been associated with 
mitochondrial oxidative stress [16, 25-28]. Increased cytoplasmatic Ca2+ levels 
may increase mitochondrial RONS formation by several mechanisms; these 
include the enhancing of citric acid cycle activity and NADH formation [26], 
activating ROS-generating enzymes such as glycerol phosphate and α-
ketoglutarate dehydrogenase [29]; but also the enhancement of NO generation via 
activation of the eNOS enzyme and consequent respiratory inhibition [30, 31], 
and promoting the loss of cytochrome c due to the mitochondrial permeability 
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transition, which is promoted by excessive Ca2+ accumulation [32-34]. At 
molecular level, the nitro-oxidative stress could facilitate the opening of the 
mitochondrial permeability transition pore (MPTP). Activation of the MPTP 
might render the inner mitochondrial membrane permeable to protons, increasing 
the eventually need of glycolytic ATP in the attempt to maintain the 
mitochondrial membrane potential. In the absence of glycolysis, an oxidative 
damage and the associated mitochondrial dysfunction may result in energy 
depletion, manifested as an irreversible drop of membrane potential, accumulation 
of cytotoxic mediators and cell death [35]. 
Mitochondrial nitro-oxidative stress has been linked to the pathophysiology of a 
large number (>100) of human diseases (such as Alzheimer disease), as well as to 
the aging process [36]. Pathological conditions characterized by a lower 
respiratory rate, in fact, are often accompanied by enhanced RONS release: this is 
the case of respiratory deficiencies associated with neurodegenerative diseases 
and mitochondriopathies [37-39].  
1.2 Patho-physiological role of Nitric Oxide  
Nitric oxide (NO) is a gaseous biological messenger which regulates several 
physiological responses [40] including relaxation of smooth muscles [41], 
neurotransmission [42], platelet aggregation [43, 44] and inflammation [45]. 
Made of oxygen and nitrogen, it can be classified as a ROS better as a RONS. In 
the late 1980s, the labile endothelium-derived relaxing factor (EDRF) was 
unveiled to be NO [46, 47]. Many of the physiological functions of NO are 
mediated through the activation of soluble guanylyl cyclase (sGC). NO interacts 
allosterically with sGC to increase cyclic GMP (cGMP) concentration, leading to 
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cGMP-response. Murad first showed that the activation of sGC by 
nitrovasodilators could occur via the formation of NO. He was fascinated by the 
idea that a gas and free radical was regulating smooth muscle contraction and 
proposed that hormones as other endogenous factors could also act by 
releasing NO [48, 49]. About 25 years ago nitric oxide was discovered to act as an 
efficient, to a large extent reversible inhibitor of cellular respiration [50]. NO 
exerts a controlled inhibitory role on the mitochondrial respiratory chain through 
the reaction with complex I and complex IV. The interaction between NO and 
complex IV is rapid and reversible [51-55], leading under controlled conditions 
(pulses of NO) to a limited depression of OXPHOS and to activation of 
glycolysis, indeed in those cells able to sustain it [56, 57]. NO is a modulator of 
neuronal function [58, 59] and several studies have suggested that NO plays a role 
in the circadian and homeostatic regulation of sleep [60-67]. NO is also 
implicated in the pathophysiology of many diseases, such as cardiovascular 
dysfunctions [68-74], neurodegeneration [75-81], arthritis, asthma, diabetes and 
septic shock [82-85]. Evidence is growing that the toxic effect of NO resides on 
its concentration levels and on the production of peroxynitrite and other reactive 
oxygen and nitrogen species. Low concentration of NO (piconanomolar) appears 
to be by and large physiological, whereas high concentration of NO (micromolar) 
may turn to pathological. The type of biomolecule reacting with NO and, when 
occurring, the cell bioenergetic changes induced, strongly contribute to 
physiological or pathological outcomes.  
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1.2.1 NO generation and the Nitric Oxide Synthases 
Nitric oxide is produced endogenously by the nitric oxide synthase enzymes, 
NOS(s).  
NOS catalyzes the following reaction: 
 
 
 
The NOS enzyme activity take advantage of the presence of differents cofactors 
and prosthetic groups: FAD, FMN, tetrahydrobiopterin (BH4) and iron 
protoporphyrin (haem). NOS generates NO using one of the terminal N atoms of 
the L-arginine that is transformed into L-citrulline [86]. Oxidation of L-arginine to 
L-citrulline occurs via two successive mono-oxygenation reactions producing 
NGhydroxy L-arginine (NOHLA) as an intermediate [87, 88].  
Three NOSs isoforms have been identified, named according to the cell type or 
the environment where they were first detected. The constitutive NOSs (cNOSs) 
are the endothelial NOS (eNOS or NOS III) and the neuronal NOS (nNOS or 
NOS I), whereas the inducible NOS (iNOS or NOS II) is typically produced on 
stimulation of immunocompetent cells. In general the nNOS and eNOS isoforms 
are known to be constitutively expressed and their function is Ca2+-dependent. 
These enzyme releases NO, in the nanomolar concentration range, for short time 
periods in response to receptor or physical stimulation. The NO released by these 
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enzyme isoforms acts as a transduction mechanism underlying several 
physiological responses. The third isoform iNOS display a completely different 
regulation of activity: it is induced after activation of macrophages, endothelial 
cells and a number of other cells by cytokines. Once expressed, thus mainly under 
infection circunstances, the iNOS synthesizes NO, in the (high) micromolar 
concentration range and for long periods of time. Furthermore, this enzyme is 
Ca2+-independent since calmodulin (CaM) is already bound to the enzyme. The 
nNOS and iNOS have a cytosolic location and eNOS is associated to the cell 
membrane. The three distinct genes for the human NOS isoforms, exist as a single 
copy of each in the aploid human genome. The three isoforms share a 50–60% 
sequence homology and some basic features: (1) the N-terminal domain, holding 
one Fe–haem, (2) the L-arginine- and the tetrahydrobiopterin (BH4)-binding 
domains, (3) a calmodulin binding region and (4) the reductase C-terminal 
domain.  
 
 
 
 
 
Fig. 4: Schematic representation of nNOS structure (from Li Zhou, Dong-Ya Zhu; Review 2009).  
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The NOSs are homodimers consisting of two identical monomers, which can be 
functionally and structurally divided into two major domains: a C-terminal 
reductase-carboxy domain, containing binding sites for FAD, FMN and NADPH, 
and an N-terminal oxygenase-amino domain, containing the binding sites for 
haem, BH4 and L-arginine [88-91] (Fig. 4). In between the two domains of a NOS 
monomer a calmodulin binding site is located (green circle in figure 4). 
The electrons are donated by NADPH to the reductase domain of the enzyme and 
proceed via FAD and FMN redox carriers to the oxygenase domain. In the 
oxygenase domain, they interact with the haem iron and BH4 at the active site to 
catalyze the reaction of oxygen with L-arginine, generating L-citrulline and NO as 
products. Electron flow through the reductase domain requires the presence of 
bound Ca2+-Calmodulin (CaCaM) [92]. 
1.2.1.1 Regulation of NOS activity  
 Intrinsic factors 
The small acidic calcium binding protein, calmodulin (CaM) was the first protein 
shown to interact with NOS and is necessary for the enzymatic activity of all three 
isoforms [93]. Calmodulin is a member of a superfamily of structurally related 
calcium signaling proteins. Members of this superfamily share a 29-residue helix-
loophelix motif called the EF-hand that is responsible for high affinity calcium 
binding. Calmodulin has four EF-hand domains, arranged as two pairs separated 
by an eight-turn central helix. The exact mechanism of how CaM activates the 
NOS is not fully understood [94]. Studies have shown that CaM is placed just 
between the two domains of the enzyme (reductase and oxygenase domain); on 
this basis it has been proposed that CaM acts like a switch that causes a 
conformational change in the NOS thus allowing the transfer of an electron 
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between the reductase and oxygenase domains, by a process that is thought to be 
highly dynamic. Under physiological conditions, the calmodulin (CaM)-binding 
site of the iNOS is always occupied by CaM, whereas CaM binding to nNOS and 
eNOS is dependent on the increase of intracellular calcium. The nNOS and eNOS 
differ in their primary structure from iNOS in the former having 40 ± 50 amino 
acids inserts in the middle of the FMN-binding subdomain, which has been 
described as an autohinibitory loop [95]. Analysis of mutants of cNOS with this 
loop deleted has shown that the insert acts by destabilizing CaM binding at low 
Ca2+ and by inhibiting the electron transfer from flavin domain to the heam 
domain in the absence of CaCaM [96]. Factors stimulating an intracellular Ca2+ 
increase, stimulate also CaM binding to cNOS that became activated. In contrast, 
when intracellular Ca2+ concentrations decrease to basal levels, calmodulin 
dissociates from cNOS and it becomes inactive.  
Extrinsic factors 
Several extrinsic factors regulating NOS(s) activity have been identified and here 
below summarized.  
- Phosphorilation 
cNOS activity is regulated by phosphorilation. The eNOS is target of 
phosphorylation at the level of key residues, namely serine Ser116 and Ser1177 and 
threonine Thr495 (human enzyme, numbering). Phosphorylation increases the 
eNOS sensitivity to Ca2+ and modulates its catalytic function, although with 
mechanisms only partly understood [97]. In contrast, the phosphorylation of 
nNOS at Ser847 by CaM-dependent kinases leads to a decrease in nNOS activity 
[98]. 
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- Proteins binding to PDZ domain of nNOS 
The N-terminal 220 aminoacids of nNOS realise a PDZ domain (post-synaptic 
density protein, discs-large/ ZO-1 homology domain) [99]. The nNOS PDZ 
domain contains two non-overlapping binding sites, one site binds PDZ domains 
of other proteins (residues 100–130, comprising a β-hairpin) while the other site 
binds COOH-terminal peptide ligands [100]. Proteins bearing PDZ domains 
typically localize to specialized cell compartments and are believed to be 
important in linking components of signal transduction pathways in multiple 
complexes [101]. The result of anchoring nNOS to membrane or cytosolic protein 
via direct PDZ–PDZ domain or C-terminal-PDZ interactions, leads to an altered 
NO signaling. PSD95 (post-synaptic density protein-95), a multivalent synaptic 
scaffolding protein, can link nNOS to N-methyl-D-aspartate receptor (NMDAR), 
and accounts for the efficient activation of nNOS by NMDAR stimulation [102].  
- Protein inhibitor of NOS (PIN) 
The initial report suggested that the N-terminus of nNOS (amino acids 163–245) 
could bind to the 89-aminoacid protein PIN which destabilizes nNOS dimers and 
inhibits nNOS activity [103]. PIN was only co-immunoprecipitated with nNOS 
and not with eNOS or iNOS [103]. However, other report claim that PIN neither 
inhibits nNOS nor promotes monomerization. Alternatively PIN might act as a 
dynein light chain, participated in nNOS axonal transport rather than as a nNOS 
inhibitor [104]. It remains to be established whether PIN can influence nNOS 
activity and if so, the mechanism involved.  
- Heat-shock protein 90 (Hsp90) 
Heat shock protein 90 (hsp90), an abundant molecular chaperone (constituing 
almost 1~2 % of total cytosolic protein) is highly conserved from prokaryotes to 
eukaryotes, and is involved in the folding, stability and maturation of numerous 
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client proteins including NOS [105]. Hsp90 has been identified as a regulator of 
eNOS activity, possibly as an allosteric modulator [106]. The nNOS-hsp90 
heterocomplex has been detected; but rather than a direct activation of nNOS by 
hsp90 wasn’t observed, it has been suggested for the chaperone protein in the 
process of incorporation of the haem into nNOS [107]. Regarding to the iNOS 
isoform, this is thought to be primarily regulated at transcriptional level and the 
identification of a protein interacting with iNOS in the central nervous system has 
been reported [108]. 
- Myristoylation, palmitoylation 
Of the three NOS isoforms, only the eNOS was found to be acylated by both 
myristate and palmitate [109]. eNOS undergoes a series of covalent modifications, 
including co-translational N-myristoylation at Gly2, as well as post-translational 
thiopalmitoylation at Cys15 and Cys26 [110, 111]. Myristoylation of eNOS is 
required for the subsequent palmitoylation of the enzyme, and both acylations are 
required for the efficent localization of eNOS to the plasmalemmal caveolae 
[112]. Specifically, eNOS is associated with caveolin-1 and caveolin 3 isoforms in 
endothelial cells and cardiac myocytes, respectively [113]. Relevant to the 
melatonin chemistry here presented, caveolin negatively impact the eNOS activity 
through a direct interaction with the enzyme. When interacting with caveolin, 
eNOS is in an inactive form. CaM acts as a direct allosteric competitor (vs 
caveolin) to promote the Ca2+-dependent activation of eNOS [114]. 
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1.2.2 NO reactivity  
NO is a highly diffusible molecule, freely permeable to membranes. Once NO is 
produced it may reacts with a large number of targets according to the specific 
kinetic and affinity constants (Fig. 5).  
 
 
 
Fig. 5: Cell targets of NO and RONS. The affinity of NO for the targets decreases from left to 
right. sGC, soluble guanylate cyclase; CcOX, cytochrome c oxidase; Nht, nonheme targets; 
RONS, reactive oxygen and nitrogen species; Prt, proteins; Lip, lipids; Nac, nucleic acids and FeS 
centres (from Sarti P., 2013).  
 
NO reacts rapidly and with high affinity to ferrous iron (Fe2+) of haemproteins 
such as guanylate cyclase, haemoglobin, myoglobin and cytochrome c oxidase. 
The reaction is: 
NO + Fe2+ ↔ Fe2+-NO 
 
The binding of NO to the ferrous iron (Fe2+) occurs with a mechanism similar 
only overall to that of CO and O2; interestingly, the kinetic binding constant is 
very similar to that O2 binding (k’ ~ 107- 108 M-1 s-1), and faster than CO binding 
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to the ferrous iron (k’ ~ 104 M-1 s-1). In order to carry out its physiological action, 
NO has to bind efficiently to the target enzyme but also to leave it rapidly. In vivo 
the dissociation of NO from the ferrous haem iron of both guanylate cyclase and 
cytochrome oxidase is very rapid, with rate constant values k’ = 0,05 s-1 [115] and 
k’ = 1,2 x 10-2 s-1 [116], respectively. 
Many of the physiological functions of NO in the cardiovascular, neuronal, 
gastrointestinal and other systems are mediated by the binding to the ferrous haem 
iron of soluble guanylyl cyclase (sGC) [41]. Among targets, indeed sGC presents 
the highest affinity for NO, with a Kd in the sub-µM range [117]; following 
binding to NO, a 200 fold increases activity of sGC occurs [118] while the 
reaction of NO with other haemproteins, such as cytochrome oxidase [51] and 
aconitase [119] induces their inhibition.  
NO can also bind to the porfirinic Fe(III) of meta-haemoglobin; in this reaction an 
electron is transferred from NO to the ferric iron forming Fe (II) NO+. The 
reaction is: 
NO + Fe3+ ↔ Fe3+-NO ↔ Fe2+-NO+ 
Differently from the bent Fe2+-NO geometry, a linear geometry of the Fe3+-NO 
bond is favoured [120]. NO binds less tightly to ferric, compared to ferrous iron 
and the NO dissociation from the Fe3+-NO complex is much faster than for the 
respective Fe2+-NO complex. It is worth noticing that some Fe3+-NO complexes 
are quite stable (e.g. catalase, horse radish peroxidase, cytochrome c peroxidase), 
whereas others (e.g. metmyoglobin, methaemoglobin, cytochrome c) react further 
[119]. 
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1.2.2.1 NO, haemoglobin and myoglobin 
The reaction of NO with oxygenated myoglobin is rapid (k= 5 × 107 M−1 s−1) and 
results in the formation of nitrate and Met-Mb. The reaction is: 
 
Mb (Fe2+)O2 + NO → Mb (Fe3+) + NO3 
 
A physiological role for this reaction was first proposed by Brunori, who 
hypothesized that the oxygenated myoglobin has high capacities of NO 
scavenging and may, therefore, protect tissues from NO-mediated inhibition of 
mitochondrial respiration, if necessary [121].  
In addition deoxygenated myoglobin possess a nitrite reductase activity. The 
reaction is: 
 
NO2− + deoxyMb (Fe2+) + H+ → NO + metMb (Fe3+) + OH− 
 
This is a slow reaction (k = 12 M−1s−1 at pH = 7.4, T = 37°C) generating metMb 
and NO, thus participating in nitrite recycling. 
1.2.2.2 The S-nitroso compounds (R-SNO) 
NO may reacts with thiols producing S-nitrosothiols (R-SNO).  
The reaction is: 
R-SH + NO ↔ R-SNO 
 
S-nitrosothiols are nitro-thio-esters with the general structure R-S-N=O; naturally 
occurring examples include S-nitrosocysteine, S-nitrosoglutathione and S-
nitrosoalbumin, in which R is an amino acid, a polypeptide and a protein, 
respectively. The R-SNO concentration in blood is 5-7 µM  but probably this 
value is overestimated [122]. R-SNO play an important role in plasma and in 
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circulating erythrocytes, where they are believed to act as a buffer and transport 
systems for NO, involved in the regulation of vascular tone and blood flow [123].  
1.2.2.3 The nitrotyrosine 
Protein bound L-tyrosines are prone to be attacked by reactive nitrogen 
intermediates to form 3-nitrotyrosine (3-NT), leading to a post-translational 
modification. Tyrosine is modified in the 3-position of the phenolic ring through 
the addition of a nitro group (NO2) [124]. ONOO-  is the most widely RONS 
involved in protein nitration [125]; the formation of nitrotyrosine has been 
detected in various pathological conditions including atherosclerosis, myocardial 
infarction, myocarditis, heart failure, shock, diabetic complication and 
neurodegenerative and inflammatory disorders [126-128].  
1.2.3 NO and mitochondrial respiration 
About 25 years ago, it was discovered that nitric oxide inhibits mitochondrial 
respiration by reacting with respiratory chain complexes, particularly with 
Complex I and IV [50, 51, 129-131]. The reaction of NO with Complex III has 
been also described, but it is sluggish [132]. The reaction of NO with Complex I 
and Complex IV has been studied in detail and, presently, appears to be the most 
promising to elucidate the bioenergetic relevance of the mitochondrial nitrosative 
stress to cell pathophysiology. Depending on a variety of parameters, it is now 
evident that the  reaction of NO with mitochondrial respiratory complexes causes 
positive or negative effects. The first ones elucidated were the inhibitory negative 
effects, though later on also signaling-like positive effects were found. The 
predominance of positive or negative effects  is, indeed, different and testifies the 
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existence of different reaction mechanisms, whose predominance directly depends 
on the actual concentration and persistence in the mitochondrial environment of 
NO. The cellular concentration of NO depends, first of all, on NOS activity, 
controlled by different stimuli and effectors; relevant to its bioavailability, 
however, NO is also produced by recycling cell’s and body’s nitrite.  
The functional implication of the reactivity of NO at the level of the respiratory 
chain is different owing not only to the protein complex targeted (Complex I 
and/or complex IV), but also and particularly dealing with complex IV to the 
reaction mechanism undergoing. Both Complex I and IV are inhibited by NO, 
though in a well different way: inhibition of complex IV is rapid (milliseconds) 
and reversible, occurring at nanomolar NO concentrations, whereas inhibition of 
complex I occurs after a prolonged exposure to higher NO concentrations and is 
persistent. The inhibition of Complex I involves the reversible S-nitrosation of a 
key cysteine residue on the ND3 subunit. The reaction of NO with cytochrome c 
oxidase (CcOX) directly involves the active site of the enzyme: two mechanisms 
have been described leading to formation of either a relatively stable nitrosyl-
derivative (CcOX-NO) or a more labile nitrite-derivative (CcOX-NO2-) [8, 116]. 
Following NO inhibition of respiration, the O2 consumption and thereby the 
OXPHOS dependent synthesis of ATP may decrease while glycolysis takes place 
[133].  
1.2.3.1 NO and Complex I 
At (high) µM concentrations, as typically in the presence of activated iNOS, NO 
inhibits complex I via the S-nitrosation of critical thiol residues [131]. Inhibition 
of complex I can be reverted by destabilizing the S-nitrosothiols. This is achieved 
with thiol-reducing agents such as dithiothreitol in vitro, or ascorbate and GSH in 
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cells and in vitro as well as in vivo [134]. The S-nitrosation of Complex I crucially 
depends on the structural conformation of the complex, which in turn depends on 
the availability of O2 and mitochondrial NADH [135]. Complex I can assume an 
active (A) form and a so-called dormant (D) or de-activated form [136]. The 
cysteine residues exposed at the surface of the enzyme are different in the A and 
D conformation [137]. The A-form exposes several (up to 10 - 15) cysteine 
residues, whose S-nitrosation or derivatization with thiol-blocking agents, such as 
N-ethyl maleimide (NEM), is almost ineffective [138]. Once in the D-state, the 
enzyme exposes on the surface of the mitochondrially-encoded ND3 subunit the 
residue cys 39 whose blockage fully inhibits the enzyme [137]. Thus the A to D 
conformational change of Complex I, provides a feasible mechanistic 
interpretation of its inactivation by NO observed in turnover and under conditions 
favoring nitrosative stress. Complex I upon reacting with NO may trigger cell 
physiological or pathological events [131, 139, 140]. Complex I inhibition has 
been observed particularly during sepsi [141]; it has been also reported to play a 
role in the progression of neurodegenerative diseases (such as Alzheimer disease 
(AD), Parkinson disease (PD) and amyotrophic lateral sclerosis (ALS)) (see [140] 
for review).  
1.2.3.2 NO and Complex IV 
Nitric oxide, at low (nM) concentrations, reacts very rapidly with complex IV 
(CcOX), producing important physiological and pathological effects at 
mitochondrial level [130]. This reaction has been studied at all integration levels 
ranging from the isolated enzyme, to mitochondria, cells and tissues [31, 51, 82, 
129, 130, 142-149]. The reaction of NO with CcOX involves the catalytic metals 
in the active site of the enzyme, i.e. the Fe and Cu ions of the haem a3-CuB site 
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[53, 150]. It can occur through two alternative reaction pathways (PWs), named 
PW1 and PW2 [8, 151]. PW1 leads to a CcOX-mediated NO oxidation to nitrite, 
whereas PW2 is responsible for formation of the more persistently inhibited, 
Fe2+–NO, nitrosyl CcOX [116]. One pathway can prevails over the other 
depending on NO, cyt c2+ and O2  concentrations (Fig. 6). Interestingly, PW2 
proved to occur only in the presence of higher concentrations of reduced 
cytochrome c ([151] and ref. therein citated) and/or during hypoxia [152], 
whereas under standard condition the formation of the nitrite derivative has been 
demonstrated to take place. 
 
 
 
Fig. 6: Two alternative reaction pathways for the interaction of NO with CcOX (from Sarti P., 
2013). 
 
Despite small or even no changes in the mitochondrial respiratory efficiency 
caused by PW1, the persistence of NO in the environment may induce a transient 
(physiological) shift to glycolysis (PW1) or a more severe (cell dangerous) 
inhibition of the respiratory chain (PW2) [8] 
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- The ‘nitrite’ pathway (PW1) 
NO reacts with the fully oxidized O binuclear site of CcOX [153] [154] or with 
the same site in the oxi-catalytic intermediates (P and F) generated during 
reaction of the enzyme with O2 [155, 156], to form nitrite (NO2-). During the 
reaction with the oxidized CuB (k = 2 x 105 M−1 s−1at 20 °C), NO is transiently 
oxidized to nitrosonium ion (NO+), that in turn is subsequently hydroxylated (or 
hydrated) to nitrite (or nitrous acid). Thus, after the reaction, the enzyme displays 
nitrite bound to ferric heme a3 and is inhibited. The affinity of nitrite for the 
reduced heme a3, however, is much lower than the affinity for the oxidized active 
site. The intramolecular electron transfer to heme a3-CuB, therefore, causes the 
prompt dissociation of nitrite and the subsequent full restoration of activity [156, 
157]. Relevant to possible patho-physiological effects of CcOX inhibition by NO, 
it is worth to notice that the nitrite dissociation upon reduction of heme a3 (~ 6 x 
10−2 s−1 at pH = 7.3, T = 20°C) is faster than the NO dissociation from the 
nitrosylated site [156, 158, 159]. A recent evidence was provided in favor of a 
nitrite reductase activity of CcOX [160-162]. Torres et al. [155] and Giuffrè et al. 
[156] established that a fairly rapid reaction of NO also occurs with intermediates 
P and F of CcOX. With these intermediates the NO reaction is slower than with 
the O species (k ~ 104 M-1 s-1 vs k = 2 x 105 M-1 s-1 at 20°C), still leading to nitrite-
inhibited CcOX.  
- The ‘nitrosyl’ pathway (PW2) 
NO binds to the fully reduced (R) binuclear site of CcOX very rapidly at a rate  
similar to that of O2 (k = 0.4 - 1 x 108 M-1 s-1) [163, 164]; the high affinity Fe2+ 
nitrosyl adduct (a32+NOCuB+) is formed [165, 166]. The dissociation reaction is 
relatively slow (koff = 3.9 x 10-3 s-1 at 20 °C) and photosensitive [116]. The fully 
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reduced (R) binuclear site commonly reacts with O2, thus the inhibition of CcOX 
via formation of a nitrosyl R-adduct is expected to occur in competition with O2. 
Under these conditions, the inhibition reverts upon exposing the inhibited enzyme 
to O2; indeed, the rate of activity recovery matches that one of NO dissociation 
from reduced heme a3. The reversal of inhibition has been proposed  to involve 
formation of superoxide (O2-) produced by reaction of O2 with reduced CuB 
reacting, in turn, with the NO molecule bound to heme a3, to yield peroxynitrite 
(ONOO-) [159]. According to this hypothesis, the peroxynitrite formed at the 
active site would be rapidly reduced to nitrite, and eventually released as such in 
the bulk. Although intriguing, a more recent study disproved this mechanism, 
showing that recovery of CcOX activity more simply results from O2-mediated 
displacement of NO bound to reduced heme a3 [167]. NO has been suggested to 
combine also with the single-electron reduced (E) site, in which the electron 
resides either on heme a3 or on CuB [166, 168].  
1.2.3.3 Mitochondrial respiration, NO and bioenergetic implications 
Different studies using isolated mitochondria [142, 169] and intact cells [56] have 
shown that inhibition of respiration by NO induces the immediate collapse of 
mitochondrial membrane potential, inhibition of mitochondrial ATP synthesis and 
depletion of ATP. Experiments carried out with exogenous NO donors showed 
that the reversible inhibition of respiration induced by NO was confined to CcOX 
[170]. As already mentioned, however, after prolonged exposure to NO, the 
respiratory chain inhibition becames persistent and is mainly localized at Complex 
I. Inhibition of CcOX by NO enhances the formation of superoxide anions  and 
subsequent generation of hydrogen peroxide that can induce the stabilization of 
HIF-1α [171]. This could explain, at least in part, the increased stability of HIF-1α 
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that is observed during treatment with NO. The increase in superoxide-anion 
generation by the electron-transport chain in the presence of NO might also 
explain the local formation of peroxynitrite observed under some circumstances 
and hence its pathophysiological relevance [125, 172, 173]. Almeida and co-
authors compared the responses of rat cortical astrocytes and neurons to nitric 
oxide mitochondrial inhibition [56]. Neurons and astrocytes are two cell types that 
differ greatly in their ability to invoke anaerobic glycolysis under stress. In both 
cell types, inhibition of respiration by NO decreased the ATP concentrations by  ~ 
25 %, and within 10 minutes. This resulted in the stimulation of anaerobic 
glycolysis in astrocytes, but not in neurons. Astrocytes responded to inhibition of 
respiration by increasing their glycolytic metabolism, and by using glycolytically-
generated ATP to maintain their mitochondrial membrane potential. Lymphoid T 
cells, which, like astrocytes, are highly glycolytic, were previously reported to 
exhibit a similar response to NO [174]. These cells were protected against 
apoptosis that is induced by the protein-kinase inhibitor staurosporin. By contrast, 
in neurons, ATP concentrations and the membrane potential continued to decrease 
and the cells showed signs of early apoptotic cell death. Further studies into this 
differential response led to the observation that, following inhibition of 
respiration, astrocytes undergo a rapid, cGMP-independent increase in the activity 
of 6-phosphofructo-1-kinase (PFK1), a master regulator of glycolysis [175]. The 
rate of activity of this enzyme in astrocytes was found to be twice of the neuronal 
one, under basal conditions. The concentration of fructose-2,6-bisphosphate 
(F2,6P2), the powerful allosteric activator of PFK1, was also significantly greater 
in astrocytes than in neurons and, following inhibition of respiration, the 
concentration increased further in astrocytes but did not change in neurons. The 
increased glycolytic rate in astrocytes served to preserve cells from ATP depletion 
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and cell death, possibly because glycolytic ATP served to drive the reverse 
activity of ATP synthase in order to maintain the mitochondrial membrane 
potential [56]. All together, these set of correlations suggest that the inhibition of 
mitochondrial respiration by NO would up-regulate the glycolytic flux in 
astrocytes to prevent the depletion of ATP. In contrast, cortical neurons showed 
that the glutamate-receptor activation, leading to NO release, causes a loss of 
mitochondrial membrane potential [176]. In addition to that, the enhancement of 
mitochondrial Ca2+ that follows glutamate receptor activation [177, 178] 
reinforces mitochondrial membrane potential loss, causing MPTP opening. MPTP 
opening promotes the exchange of solutes and small proteins between the 
mitochondrial matrix and the cytosol [179]. These events all coexist and lead to 
mitochondrial swelling, rupture of the outer mitochondrial membrane, and release 
of pro-apoptotic factors such as cytochrome c [179]. It is worth recalling also that 
the prolonged exposure of cells to NO and/or to peroxynitrite might induce the 
depletion of the intracellular reduced glutathione, thus rendering mitochondria 
more vulnerable to the deleterious effects of RONS. Furthermore, it has been 
shown that the generation of intracellular NO during exposure of neurons to 
glutamate results in a progressive depletion of NADPH, contributing to the 
decrease of the reduced/oxidized glutathione ratio. In addition, the activity of 
cytoplasmic enzymes, such as glutathione reductase and glyceraldehyde-3-
phosphate dehydrogenase is, like complex I, inhibited by NO in a manner that 
indicates the occurrence of S-nitrosylation [174]. The action of endogenous NO 
on mitochondrial respiration provides the clue to understand both the 
physiological bioenergetic regulation and the activation of cellular response to 
energy failure; indeed, under some extreme circumstances, such as ischemia, 
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hypoxia or altered composition of the respiratory chain, the reaction of Complex 
IV with NO may become pathological.  
1.3 Melatonin 
Melatonin (Fig. 7), the N-acetyl-5-methoxytryptamine, is an hormone, secreted 
mainly by the pineal gland, but also produced in many other sites such as retina, 
skin, gut, and bone marrow cells, although the physiological implication of the 
extrapineal synthesis is only beginning to be revealed [180, 181].  
 
 
 
Fig. 7:  Chemical structure of melatonin (from Ambriz-Tututi et. Al, 2009). 
 
Melatonin was discovered in 1956 by the American dermatologist Aaron Lerner 
and his co-authors as an amphibian skin-lighting factor present in extracts of 
bovine pineal glands [182]. Subsequently, melatonin was reported to be present in 
a wide spectrum of organisms, including bacteria, fungi, plants, protozoa, 
invertebrates and vertebrates, including man [183-185]. The fact that melatonin is 
evolutionarily highly conserved molecule suggest for this molecule an important 
physiological role(s). In humans, melatonin secretion by the pineal gland is 
synchronized to the light ⁄ dark cycle, with a nocturnal maximum (in young 
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subjects, ≈ 200 pg x mL-1 plasma corresponding to ~ 1 nM) and low diurnal 
baseline levels (≈ 10 pg x mL-1 plasma corresponding to ~ 50 pM) [186, 187].  
1.3.1 Biosynthesis and catabolism 
The enzymatic machinery for the biosynthesis of melatonin in the pineal gland 
pinealocytes was first identified by Axelrod (Fig. 8) [188]. Melatonin is 
synthesized from a dietary amino acid precursor, L-tryptophan, through the action 
of four enzyme: tryptophan hydroxylase (TPH), aromatic aminoacid 
decarboxylase (AADC), arylalkylamine N-acetyltransferase (AA-NAT) and 
hydroxyindole-O-methyltransferase (HIOMT). The rate of melatonin formation 
depends on the activity of the two enzymes AA-NAT [189, 190] and, to a lesser 
extent TPH, which controls the availability of serotonin [191, 192]. In mammals, 
the regulation of pineal melatonin biosynthesis is mediated by the 
retinohypothalamic tract, whose signal activates the suprachiasmatic nucleus 
(SCN) [193]. Postganglionic sympathetic fibers reach the pineal gland and 
regulate melatonin biosynthesis through the presynaptic release of norepinephrine 
(NE) [194]. NE, by binding to β-adrenergic receptors on the pinealocytes, 
activates adenylate cyclase via the α-subunit of G(s) protein. The increase in 
cAMP promotes the synthesis of proteins, among them the melatonin-synthesizing 
enzymes, and in particular the rate-limiting AA-NAT [195]. The nocturnal 
exposure to bright light suppresses melatonin production immediately by 
degradation of pineal AA-NAT (Fig. 8b) [196]. Pineal melatonin production 
occurs during the dark phase and is acutely suppressed by light and in addition 
melatonin is quickly cleared from the circulation following the cessation of its 
production, therefore, for both reasons, plasma melatonin exhibits a circadian 
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rhythm: highest levels occurs at night, and lowest levels during the day, attaining 
peak plasma concentrations between 02:00 and 04:00 h [197] (Fig. 8c). 
 
 
 
 
Fig. 8: a) Pineal gland. b) Melatonin biosynthesis by pinealocyte. c) Averege human melatonin 
rhythm. D) Age-related diminution of night melatonin rise (modified from Reiter, 1991). 
 
The onset of secretion is usually at ~ 21.00 to 22.00 h and the offset at 07.00 to 
09.00 h in adults, leaving in temperate zones [197, 198]. Due to its lipophylic 
nature, melatonin readily crosses the blood–brain barrier. Once synthesized, the 
majority of melatonin diffuses directly towards the cerebrospinal fluid of the 
brain's third ventricle, while another fraction is released into the blood stream, 
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whereby it is distributed to all tissues [180, 199]. Melatonin released to the 
cerebrospinal fluid is ~ 20–30 times higher than that released into the blood. More 
than 90% of circulating melatonin is degraded by the liver; in the hepatocyte is 
first hydroxylated in the C6 position by cytochrome P450 mono-oxygenases 
(isoenzymes CYP1A2, CYP1A1 and, to a lesser extent, CYP1B1) being, 
thereafter, conjugated with sulfate, to a lesser extent with glucuronic acid, to be 
excreted as 6-sulfatoxymelatonin (aMT6S) in urine [180].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9: The metabolism and the antioxidant cascade of melatonin. Circulating melatonin is 
metabolized to 6-sulfatoxymelatonin (6-OHM) in the liver. In the brain, melatonin is metabolized 
to N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) through the pyrrol-ring cleavage. When 
melatonin interacts with RONS it generates cyclic 3-hydroxymelatonin (c3-OHM). The c3-OHM 
acts likewise a scavenger, leading to the formation of AFMK. AFMK interacts with RONS to form 
N1-acetyl-5-methoxykynuramine (AMK); this latter molecule is a radical scavenger as well. This 
cascade of reactions greatly enhances the effective functional concentration of melatonin and  its 
scavenging efficacy (modified from Reiter et al., 2009). 
 
liver 
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The metabolism of melatonin is rapid, and its half-life in humans following 
exogenous administration is short, ranging between 10 and 60 min [200] (Fig. 9). 
In the brain, a substantial fraction of melatonin is degraded via oxidative pyrrole-
ring cleavage and is metabolized to N1-acetyl-N2-formyl-5-methoxykynuramine 
(AFMK) [201]. Melatonin can be also metabolized non-enzymatically in the cells, 
but also extracellularly, by mean of a free radical chemistry and a few other 
oxidants. Melatonin is converted into cyclic 3-hydroxymelatonin (c3-OHM) by 
directly scavenging two hydroxyl radicals. The c3-OHM itself is an effective 
radical scavenger and generates AFMK. AFMK is not the terminal molecule in 
melatonin’s antioxidative cascade. Rosen and co-authors have documented that it 
interacts with RONS to form N1-acetyl-5-methoxykynuramine (AMK) [202]. This 
latter molecule is a radical scavenger as well. This is of interest as the antioxidant 
and anti-inflammatory properties of melatonin are shared by these metabolites, 
AFMK and, with considerably higher efficacy AMK [203, 204].  
1.3.2 Physiological role 
Melatonin is involved in various physiological functions [187, 201, 205, 206], 
such as sleep propensity [207], control of sleep ⁄ wake rhythm [208], blood 
pressure regulation  [209], energy metabolism [210], immune function [199, 211], 
circadian rhythm regulation [212], retinal functions [189], detoxification of free 
radicals [203, 204, 213], control of tumor growth [214],  bone protection [215] 
and the regulation of bicarbonate secretion in the gastrointestinal tract [216]. 
Melatonin was initially studied for its role in endocrine physiology regulating 
circadian and, sometimes, seasonal rhythms [217]. It acts as a photoperiod 
messenger molecule, transducing photoperiod changes to reproductive organs, and 
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plays a vital role in the seasonal control of reproduction in certain animals. 
Melatonin participates in reproductive function by acting at hypothalamic, 
pituitary and gonadal levels [218, 219]. Melatonin may have a significant role in 
the onset of human puberty [220]. Melatonin can be used as a chronobiotic that is 
capable of normalizing the disturbed bodily rhythms, including sleep–wake 
rhythms [201, 221, 222]. In fact, melatonin is used for preventing jetlag or as 
adjuvant in elderly people with sleep-problems [205]. The direct effects in region 
containing high density of melatonin receptors, such as the circadian pacemaker, 
the suprachiasmatic nucleus (SNC), or the pars tuberalis (PT) strongly supported 
the original hypothesis of its physiological role. In the perception by many 
investigators, the control of circadian and seasonal rhythmicities represents 
melatonin’s main physiological function. Although this view is not generally 
disputed, during more recent decades, melatonin has been shown to possess a 
number of additional functions and to act in tissues or cells that express melatonin 
receptors at much lower level [187, 201, 206, 223]. Several evidence has been 
accumulated showing that melatonin influences the function of a variety of tissues 
not related to the endocrine system [217] and display an exceptional multiplicity 
of actions. The presence of melatonin in the gastrointestinal tract suggests that it 
has a protective role in this organ system [224]. Melatonin has significant bone-
protecting properties [225] and plays a role in energy expenditure and body mass 
regulation [226]. Melatonin has been demonstrated as an efficient antioxidant 
under both in vivo and in vitro conditions. Not only melatonin, but also the 
kynuric pathway of melatonin, provides a series of radical scavengers [204]. 
Melatonin up-regulates antioxidative enzymes. The complex pattern of protective 
actions of melatonin may turn out to be of major clinical significance, for example 
in retarding the progression of neurodegenerative diseases such as Alzheimer’s or 
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Parkinson’s disease [227-229]. Deficiencies in melatonin production or melatonin 
receptor expression, and decreases in melatonin levels (such as those which occur 
during aging) can be associated with a multitude of pathophysiological changes, 
which, again, reflect the pleiotropy of this molecule. Changes in the amplitude 
and phasing of the melatonin rhythm have been described in patients with major 
depressive, bipolar affective, mood and seasonal affective disorders. Melatonin 
reduces the systolic, diastolic and mean blood pressure of hypertensive patients 
[230, 231]. The antitumor effects of melatonin seem to be exerted at multiple 
levels, from modulation of the glutathione system to interference with lipid 
mediators and receptors of other hormones [232-235]. The immune-enhancing 
actions of melatonin, in conjunction with its antioxidant properties, suggest a 
therapeutic value in a variety of diseases, including bacterial and viral infections 
[199, 201]. In comparison with other signaling molecules, the numerous actions 
that have been attributed to melatonin are exceptional. This should be taken as an 
expression of its overall importance as a modulator at various levels of hierarchy. 
The practical applicability of melatonin, however, remains unconfirmed in fact 
most of the effects described have not been demonstrated at clinically relevant 
concentrations. Moreover, a pleiotropic agent may have side-effects, which, to 
date, have still not been investigated in detail.  
1.3.3 On the cell stage 
Melatonin interacts with cells in a receptor-dependent or -independent manner 
(Fig. 10). The receptor-mediated melatonin signaling involves different types of 
cell surface and nuclear receptors, expressed to a different extent by cell-lines and 
tissues. Several major actions of melatonin are mediated by the membrane 
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receptors MT1 (Mel 1a) and MT2 (Mel 1b) [205, 223]. They belong to the 
superfamily of G-protein coupled receptors containing the typical seven 
transmembrane domains. The human MT2 receptor has a lower affinity (Kd = 160 
pmol/l) for 125I-melatonin as compared to the human MT1 receptor (Kd = 20–40 
pmol/l); both are, therefore, of a fairly high affinity and the agonist binding is 
guanosine triphosphate (GTP)-sensitive [223]. Activating G protein signaling, 
specifically Gi/Go, the receptors mediate a wide variety of effects; among others, 
inhibition of the adenylate cyclase (AC), with a consequent cyclic AMP (cAMP) 
decrease, regulation of gene transcription, activation of protein kinase C subtypes 
and changes of intracellular Ca2+ levels [205]. MT1 and MT2 receptors are 
expressed both singly and together in various tissues of the body [223]; also their 
mRNA levels vary on a circadian basis, with expression levels affected by light 
and melatonin concentration in plasma. Besides membrane receptor signaling, 
melatonin has been extensively proposed to freely cross the cell membrane [236], 
to reach and interact with subcellular components, such as nucleus [237] and 
mitochondria [210]. This suggests the potential for melatonin to widely interact 
with low affinity intracellular enzymes, transporters, cytoskeletal proteins, and 
nuclear receptors, which can generate further signals independently or by 
secondary interaction with components of receptor-dependent pathways. The 
enzyme quinone reductase 2 is a classic example of these protein targets that was 
originally identified as a third melatonin receptor (MT3) with possible regulatory 
functions on cellular redox status [238]. However, the biochemical characteristics 
and physiological role of this low-affinity binding protein remain poorly 
understood [239]. Melatonin binds nuclear (orphan) receptors of the family of 
RORs and RZRs (RZR/RORa) regulating the expression of several enzymes. 
Members of these families have been suggested to play a role in the 
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immunostimulatory effect of melatonin in B and T lymphocytes, by sustaining its 
potential to inhibit Fas ligand-mediated apoptosis and cytokine production [240]. 
RORα inactivation by melatonin has been proposed to follow its interaction with 
calmodulin, an upstream component of melatonin signaling, and it is ultimately 
responsible for the control of transcription factor NF-kB-dependent genes 
including, among others, inflammatory mediators and antioxidant enzymes [241]. 
 
 
 
Fig. 10: Melatonin on the cell stage (from Sarti P., 2013). 
 
Binding nuclear receptor melatonin also down-regulate pro-oxidant enzymes, 
such as the NOSs, particularly the iNOS [242]. Although antioxidative protection 
by melatonin is partially based on receptor mechanisms, Tan and co-workers 
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reported in 1993 [243, 244] that melatonin functioned as a direct free radical 
scavenger, an action that is receptor-independent. Melatonin has the capability of 
donating electrons in vitro to reduce the reactivity of molecules with an 
unimpaired electron in their valance orbital, i.e. free radicals.  
The antioxidant properties of melatonin have been world-widely recognized, 
likely accounting for a number of protective effects exerted in different cellular 
compartments [204]. Melatonin is more effective than the majority of its naturally 
occurring molecular analogs [244, 245], suggesting that the substituents of the 
central indole structure controls the reactivity of the adducts. Rate constants 
determined for the reaction of melatonin with hydroxyl radicals are very high, 
almost diffusion limited, approaching k ≈ 1010 M−1 s−1 [246, 247]. Receptor-
independent activities of intracellular melatonin can be also sustained by low-
affinity interactions with specific targets of cell signaling. These include calcium 
binding proteins, cytoskeletal and scaffold proteins, other signaling proteins in the 
cytosol and in some organelles, and, in particular, components of mitochondrial 
signaling. Among the intracellular targets of melatonin, the Ca2+-calmodulin 
(CaCaM) complex plays a major role in both receptor-dependent and -
independent functions [248, 249]. The mitochondrion is proposed to play a key 
role in cell signaling and in the transcriptional and post-translational events 
induced by melatonin, which integrate with the signaling activity of the cell 
during normal or stress-related conditions. 
1.3.4 The mitochondrial connection 
The discovery that mitochondria are a target for melatonin opened a new 
prospective to understand the mechanism of action of this indoleamine. It is 
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generally agreed that melatonin has a role in the mitochondrial metabolic 
homeostasis [250-253]. Melatonin may be a critical molecule that preserves 
mitochondrial integrity and physiology [252]. Melatonin is accumulated in the 
mitochondrion in a concentration dependent manner [254, 255] where it interferes 
with mitochondrial bioenergetics. The highest intracellular melatonin 
concentration are found in mitochondria (~ 100–200 times more than in the 
cytosol) [256]. It has been proposed that melatonin can: (i) protect cells against 
mitochondrial oxidative stress and apoptosis through its antioxidant and RONS 
scavenging properties; (ii)  accelerate the electron flow through the mitochondrial 
respiratory chain, thus increasing the efficiency of ATP production [257, 258]; 
(iii) stabilize and optimize the membrane potential across the inner mitochondrial 
membrane by regulating the mitochondrial permeability transition pore (MPTP) 
[259-261]. The molecular mechanism(s) underlying the functional effects of 
melatonin, particularly those related to cell bioenergetics, and therefore of 
putative patho-physiological relevance,  remain as yet only partly understood. 
1.3.4.1 Melatonin and mitochondrial oxidative stress 
Melatonin has been repeatedly shown to reduce the mitochondrial formation of 
RONS thus protecting eTC proteins and mitochondrial membranes against 
oxidative, nitrosative or nitrative damage [252-254, 262, 263]. Melatonin reacts at 
a high rate with radicals like OH˙ and relatively, more slowly with the O2−. 
Melatonin is not only a potent scavenger of hydroxyl radicals, but also of NO, 
ONOO− and carbonate radicals [203, 264]. Many studies demonstrate the 
protective effect of melatonin and its derivatives on lipid peroxidation induced by 
oxidative stress in mitochondrial membranes [265]. It is presumed that melatonin 
achieves this high degree of lipid protection by interfering with the radicals that 
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initiate this process, especially the OH˙ and ONOO-, and by positioning itself 
among the membrane lipids in such a way as to impede the oxidation of the 
polyunsaturated fatty acids [266]. Melatonin was reported to protect the 
mitochondria from oxidative damage in part by preventing cardiolipin oxidation 
[210, 261]. Alterations in cardiolipin structure, content and acyl chain 
composition have been associated with mitochondrial dysfunction in various 
tissues under a variety of pathophysiological conditions [210, 262]. The 
antioxidant effect of melatonin could be also ascribed to its ability of down-
regulating the free radical production via two different mechanisms [267]. The 
first one consists in the acceleration of the electron flow through the eTC, thus 
avoiding leakage from the chain responsible for formation of partially reduced 
oxygen species. The optimization of eTC is achieved by promoting the activity of 
complex I and complex IV, the main electron leakage sites of the chain [257, 
268]. The second one involves the control of the mitochondrial membrane 
potential. An elevated mitochondrial membrane potential slows down the eTC and 
may result in an accumulation of reducing equivalents with electron leakage 
generating free radicals. A moderate down-regulation of the mitochondrial 
membrane potential significantly reduces free radical formation [269]. Melatonin 
improves the GSH redox cycling and increases GSH content by stimulating its 
synthesis in the cytoplasm. Under normal conditions, in fact, melatonin is able to 
stimulate the expression and activity of the two enzyme involved in the GSH-
GSSG balance, i.e., glutathione peroxidase (GPx) and glutathione reductase 
(GRd) [256, 262, 270]. Up-regulation of antioxidant enzymes and down-
regulation of pro-oxidant enzymes are other mechanisms that contribute to the 
protective effects of melatonin on mitochondria. Melatonin, for instance, enhances 
the activity of superoxide dismutase [271-273], catalase [274], glutathione 
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peroxidase and heme oxygenase1 [275]. Conversely, melatonin inhibits activities 
of some pro-oxidant enzymes including iNOS [242, 276, 277], the cyclo-oxidase 
2 (COX2) and the myeloperoxidase [278, 279]. The effects of melatonin on these 
enzymes likely contribute to its protective effects against mitochondrial oxidative 
stress.  
1.3.4.2 Melatonin and respiratory complex  
The high redox potential of melatonin 0.94 V suggests that this indoleamine may 
be redox active interacting with the complexes of the eTC, thereby increasing 
electron flow. Martin and co-workers observed that pharmacological 
concentration of melatonin increases the activity of brain and liver mitochondrial 
respiratory complexes I and IV in a time-dependent manner, whereas no 
significant changes were detected at the level of Complex II and III [257]. The 
same authors extended this observation to sub-mitochondrial particles isolated 
from rats liver and brain: the organelles incubated with increasing quantities of 
melatonin, from ∼10-9 M up to ∼10-4 M showed, once again, an enhancement of 
Complex I and Complex IV activity [258]. Despite the clear experimental 
evidence, the molecular mechanism by which melatonin administered in the diet,  
injected i.p., or added to a suspension of isolated mitochondria would sustain the 
mitochondrial complexes activity is still obscure. Interestingly, and somewhat in 
contrast with these findings also a decrease of the O2 consumption rate by rat liver 
mitochondria has been reported [280]. Other studies have described one possible 
mechanism by which melatonin increases the activity of complex IV; this 
protection action may be due, at least in part, to an effect on the expression of 
mtDNA encoded polypeptide subunits I, II and III of complex IV in mitochondria 
from rat liver in a time-dependent manner which correlates with the increase in 
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complex IV activity. These effects were also produced by AMK and this 
compound was more potent than melatonin itself [281]. 
1.3.4.3 Melatonin and mitochondrial membrane potential 
Electrophysiological experiments demonstrate the antagonism of melatonin on the 
ionotropic glutamate receptor N-methyl-d-aspartate (NMDA receptor) [282, 283]. 
This effect is dose-dependent and, as a consequence of the treatment, the NMDA 
receptor channel pore remains closed, thereby preventing the opening of L-type 
calcium channels and calcium influx [284]. Further experiments demonstrate that 
melatonin is able to diminish the rises in cytosolic calcium induced by NMDA in 
cultured mouse striatal neurons [285]. Experiments carried out using rat brain 
astrocytes [286] and cultured PC12 cells [287] show that melatonin limits 
cytosolic calcium rises and, as a consequence, the concomitant production of free 
radicals. In these two reports, melatonin indirectly inhibited the opening of the 
MPTP and blocked MPTP dependent cytochrome c release, the downstream 
activation of caspase 3 and the cell death by apoptosis [286]. Melatonin strongly 
inhibits MPTP currents in a dose dependent manner with an IC50 of 0.8 µM 
[285]. Melatonin was repeatedly shown to prevent, at pharmacological 
concentrations, a fatal decline in mitochondrial membrane potential, in various 
cell types and with high efficacy against different noxes [285, 286, 288]. Recently 
it was hypothesized a dual effects of melatonin on the MPTP [263]. Under normal 
conditions, melatonin activates MPTP and mildly reduces the mitochondrial 
membrane potential [254]. Under oxidative stress conditions that damage MPTP 
function, melatonin significantly inhibits the MPTP and thus preserves the 
membrane potential to avoid mitochondrial collapse [259, 260, 289-291]. The 
dual functions of melatonin on MPTP establish the indoleamine as an excellent 
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molecule, which balances mitochondrial membrane potential and maintains the 
optimal function of mitochondria to generate ATP under both favorable and 
unfavorable conditions. 
1.3.5 Melatonin and NOS 
At least 20 years ago it has been proposed that melatonin down-regulates the NO 
synthase [276, 277, 292, 293]. Several experiments have documented the 
inhibiton of expression and activity of iNOS by melatonin [206, 276, 277, 294-
298]. Whether the effects of melatonin on iNOS are direct or depend on its 
metabolites (AMK and AMFK) remain to be tested. In any case, the decrease of 
iNOS expression by melatonin leads to a significant reduction of NO levels and of 
its toxic effects, such as the ONOO- generation [299]. Much more work has been 
published on the downregulation of iNOS in models of inflammation and sepsis 
treated with pharmacological doses of melatonin [300]. In liver and lung of LPS-
treated rats, melatonin antagonized iNOS as well as NO-dependent decrease in the 
activity of complex I and IV [299]. It was observed that melatonin administration 
had no effect on NOS activity and NO levels in mice lacking the iNOS gene, a 
finding suggesting that melatonin acts specifically on iNOS [295]. The effects of 
melatonin on eNOS expression and activity are unclear. It has been observed that 
melatonin prevents decrease of eNOS levels observed during cerebral ischemia, 
inducing, through its activation, vasodilation and vascular protection [301, 302]. 
Several experiments have shown that melatonin inhibits the activation of nNOS 
through inhibition of calcium–calmodulin complex (CaCaM), as well as through 
its binding and consequent closing of NMDA [249, 281, 296, 303]. Melatonin 
inhibits CaCaM in a receptor-dependent and independent manner. Melatonin can 
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directly bind CaCaM, avoiding the activation of the CaCaM dependent enzymes, 
including nNOS [248, 249]. The binding of melatonin with MT1/MT2 can 
regulate CaCaM activity through its phosphorilation or regulating the intracellular 
Ca2+ concentration. One of the melatonin metabolites, AMK also binds CaCaM 
and reduces nNOS activity in a dose dependent manner [249]. Interestingly, AMK 
induces an inhibition of nNOS higher than melatonin [281]. While several studies 
sustain that melatonin is an inhibitor on nNOS, recently Ortiz and co-worker 
observed that melatonin consistently inhibits the expression and activity of iNOS, 
which was related to its efficacy in preventing mitochondrial failure during sepsis 
but interestingly preserve the expression and activity of nNOS [298]. Overall, 
melatonin seems to maintain the levels of NO in a concentration range necessary 
to perform its physiological role while inhibiting the occurrence of high levels of 
NO (also to pathological concentration range). It is interesting that the C-terminal 
extremity of the MT1 receptor has been identified as containing a class III 
recognition motif for PDZ domains [304]. nNOS is another PDZ domain-
containing protein that was previously described as a potential interacting 
candidate for the MT1 receptor [305]. In this work a novel role of melatonin 
exerted on the nNOS expression and activity has been unveiled and will be 
described in details.  
1.3.6 Melatonin: physiological versus pharmacological concentration 
It could be argued by the people in favor of the antioxidant melatonin function 
that the physiological concentration of melatonin, even at night, in vivo is too low 
to be a relevant antioxidant. As a matter of fact, the circulating melatonin 
concentrations at night peak are in the low nanomolar range. It is also often 
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assumed that melatonin levels in blood are reflective of its concentrations within 
tissues and cells, i.e. that the circulating melatonin concentrations is the result of 
an equilibrium within all body compartments. This assumption is true only in part, 
since it should be considered that other body fluids, e.g. ovarian follicular fluid 
[306], cerebrosprinal fluid [307], bile [308] contain much higher concentrations of 
melatonin than blood. Moreover, as knowledge in this field grows, it became 
apparent that a large number of tissues/cells have the capability of producing 
melatonin. High levels of melatonin have been identified in mitochondria, that 
require valid protection from free radicals and the associated stress. Recently, 
evidence has emerged to show that mitochondria may have the capacity to 
synthesize and metabolize melatonin [263]. With a few exceptions [254], the 
majority of the data have been collected under µM to mM melatonin 
concentration regimes, i.e. pharmacological-like concentrations, though using a 
wide variety of experimental systems, from cell organelles, to cultured cells up to 
in vivo. Under these conditions, melatonin has been reported to induce 
optimisation of cell bioenergetics homeostasis [257], due to its mitochondrial 
accumulation [254], with a direct action on the respiratory chain complexes, and 
prevention of oxidative mitochondrial DNA damage [251]. It remains to be 
determined whether the direct free radical scavenging activity is the exclusive 
mechanism, by which melatonin abates radical-mediated molecular destruction. It 
has been proposed, alternatively, that melatonin might act indirectly as stimulator 
of antioxidant enzymes [271-275] and inhibitor of pro-oxidant enzymes, such as 
NOS [206, 276, 277, 294-298]. Whatever the mechanism is, it is argued that 
melatonin markedly reduces excessive oxidative damage, under many 
experimental and clinical conditions where the molecular distruction occurs as a 
consequence of a high free radical-related disease or to aging [309-311]. Whether 
Chapter 1. Introduction 
 
48
 
 
this protection occurs at physiological melatonin concentration, or can only be 
achieved with pharmacological doses continues to be debated [203].  
The experimental evidence suggests that the mitochondrial antioxidant melatonin 
activity is more evident at high concentration (≥ µM), while its hormonal-like 
function can be detected at the lower (≤ nM) concentrations. 
1.4 Nitro-oxidative stress and neurodegeneration 
1.4.1 Alzheimer’s disease 
Alzheimer’s disease (AD) is among the principal debilitating conditions of the 
current century, affecting around 15 million people worldwide [312]. Most of the 
cases are sporadic whereas 5-10% are familiar and associated with mutations in 
gene of proteins involved in amyloid-β (Aβ) metabolism. This disorder is an age-
related neurodegenerative disorder characterized by progressive cognitive decline, 
memory loss and neuropathological alterations. Accumulation of  extracellular 
amyloid plaques mainly composed of Aβ peptides and deposition of intracellular 
neurofibrillary tangles (NFTs) built up of hyperphosphorilated tau are the main 
features of AD. Because of this, AD has been identified as a protein-misfolding 
disease (proteopathy) caused by abnormally folded Aβ and tau protein in the 
brain. Gross brain atrophy prominent in AD is caused by massive loss of neurons 
mostly in brain regions involved in learning and memory. Although the hallmark 
lesions of the disease were described by Alois Alzheimer already in 1906, the 
molecular mechanisms underlying the disorder are still unknow and an efficient 
therapy is still missing. Many lines of evidence suggest that oxidative stress is one 
of the earliest changes and plays an important role in the pathological process in 
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AD, and more recently, energy deficiency and mitochondrial dysfunction have 
been recognized as a prominent, early event in AD [312-317].  
1.4.2 Amyloid β  
Substantial genetic, animal modeling and biochemical data have emerged to 
suggest that Aβ plays a central role in AD [318, 319]. Aβ is a 4-KDa peptide 
derived from the β-amyloid precursor protein (APP) by the action of two aspartyl 
proteases referred to as β- and γ-secretases [320, 321]. APP is a trasmembrane 
polypeptide containing a single membrane-spanning domain, a large 
ectoplasmatic N-terminal region and a shorter cytoplasmatic C-terminal region. 
During and after the trafficking through the secretory pathway APP can undergo a 
variety of proteolytic cleavages to release secreted derivatives into vescicle 
lumens and extracellular space [322]. The α-secretase cleavage of APP releases 
the N-terminal ectodomain soluble APPα from the cell surface leaving an 83-
amino-acid-long C-terminal membrane-bound fragment (C83). This fragment can 
be further processed by γ-secretase giving rise to the small peptide p3 and a C-
terminal fragment called amyloid intracellular domain (AICD). In contrast, APP 
may be cut by β-secretase to produce a soluble version of APP (β-APP) and a 99-
residues COOH-terminal fragment (C99) that remains membrane-bound. C99 is a 
substrates for γ-secretase activity, which cleaves in the middle of trasmembrane 
domain to produce the 4 KDa Aβ and AICD. Depending on the exact point of 
cleavage by γ-secretase, three principal forms of Aβ, comprising 38, 40 or 42 
amino acid residues, respectively are produced. Aβ is a natural product and is 
present in the brains and cerebrospinal fluid (CSF) of normal humans throughout 
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life [321, 323]. The levels of Aβ in the CSF are known to fluctuate as part of daily 
sleep-wake cycles [324], strongly suggesting that a dynamic balance between Aβ 
production and clearance is a normal physiological event in the brain. Thus, the 
mere presence of Aβ does not cause neurodegeneration; rather neuronal injury 
appears to ensue as an abnormally accumulation of Aβ and a result of its self-
association [325-327]. Aβ peptides are amphipathic molecules, containing a 
hydrophilic N-terminal stretch (residues 1-28) and a hydrophobic C-terminal 
domain (residues 29-40/42) [311]. In solution, Aβ display a substantially unfolded 
conformation. The misfolded Aβ usually contains stacks of β sheets organized in 
an arrangement known as a ‘cross-β’ structure. Because β-sheets can be stabilized 
by intermolecular interactions, Aβ have a high tendency to form oligomers, AβΟs  
and spontaneously assemble into amyloid protofibrils and fibrils [328]. Emerging 
studies have shown a robust correlation between soluble, low molecular weight 
AβΟs levels and the severity of cognitive impairment [329]. Aβ42 is far more 
prone to oligomerize and form amyloid fibrils than is the more abundantly 
produced Aβ40 peptide [330] and because of this the over-production of all Aβ, 
or an increased proportion of the 42 amino acid form, appears sufficient to cause 
early onset AD [331-334]. However, mechanism underlying Aβ-induced 
neurotoxicity remain to be fully elucidated. Growing evidence suggests that Aβ 
has deleterious effects on mitochondrial function and contributes to energy 
failure, neuronal apoptosis and production of RONS in AD brain [314]. 
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1.4.3 Amyloid β and mitochondria 
Extracellular soluble AβOs are believed to cause synaptic and cognitive 
dysfunction in AD [335, 336]; however, several evidences have indicated that 
intraneuronal accumulation of Aβ is an early event in AD [337, 338] and 
contributes to synaptic pathology [339-341]. In brains affected by AD, 
intraneuronal Aβ, predominantly in the form of Aβ42, has been found to 
accumulate within several organelles, including the endosomes/lysosomes [342], 
autophagosomes [343], and mitochondria [344-346]. Endoplasmic reticulum (ER) 
as well is likely a target of intracellular Aβ [347]. Intraorganelle accumulation of 
Aβ appears to damage these organelles and affects cell viability. Morphologic 
studies provide further evidence of the presence of Aβ in mitochondria [314, 345]. 
Confocal microscopy demonstrated that Aβ co-localized with HSP60, a marker of 
mitochondrial matrix. The origin of intramitochondrial Aβ is far from certain. It is 
assumed that mitochondrial Aβ is transported from other intracellular 
compartments [348-350]. This is due to cross-talk between cellular organelles 
[351], in particular between ER and mitochondria. The potential origin of 
mitochondrial Aβ, in fact, is possibly the ER and/or the endosomes/lysosomes 
[352]. It is logical to presume that Aβ might gain access into the mitochondrial 
matrix by an intracellular trafficking mechanism with involvement of a specific 
transport mechanism on the mitochondrial membrane [352]. Aβ can be imported 
into mitochondria via the TOM and TIM import machinery [312, 348, 353, 354]. 
However, Aβ has the ability by itself to permeabilize membranes. Recently, 
Rosales-Corral and co-worker found important evidence on Aβ-induced 
alterations in the lipid content of mitochondrial membranes, in part related 
possibly to a direct Aβ molecular interaction and in part related to Aβ-induced 
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oxidative stress [354]. The observation that both APP and γ-secretase 
components, including presenilin, nicastrin, Aph-1, and Pen-2, localize into 
mitochondria and that APP has a mitochondrial targeting signal sequence has 
gained attention [355, 356]. These observations indicate the possibilities that at 
least a portion of mitochondrial Aβ is generated in mitochondria and that Aβ may 
play a physiological, beneficial role for mitochondrial function. However, there is 
no evidence to confirm the physiological role of mitochondrial Aβ; instead, Aβ 
has been demonstrated to impair mitochondrial function [345, 346, 357-360]. A 
direct effect of Aβ on mitochondrial processes is further suggested by in vitro 
experiments in which cultured cells or isolated mitochondria were exposed to Aβ. 
In the micromolar concentration range, Aβ induced dose-dependent generation of 
ROS and ATP depletion associated with depolarization of the mitochondrial 
membrane, decreased oxygen consumption and inhibition of respiratory chain 
enzymes in PC12 cells [361]. A study by Tillement and co-worker showed that as 
low as 0.1 pM of Aβ42 decreased the mitochondrial respiratory coefficient in 
mitochondria isolated from rat forebrain, suggesting that Aβ impairs oxidative 
phosphorylation[362]. Moreira and co-worker demonstrated that 2 µM Aβ40 can 
exacerbate calcium-dependent formation of the MPTP, resulting in decreased 
mitochondrial membrane potential, decreased capacity to accumulate calcium, and 
uncoupling of respiration [363, 364]. Further study by Takuma and co-worker  
showed that neuronal culture from Tg mAPP/ABAD mice displays spontaneous 
generation of ROS, decreased ATP production, decreased CcOX activity, release 
of cytochrome c from mitochondria with subsequent induction of caspase-3-like 
activity followed by DNA fragmentation and loss of cell viability [365]. For 
APPOSK-transfected cells, Umeda and co-worker  demonstrated that 
mitochondrial accumulation of AβOs caused altered mitochondrial membrane 
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potential and cytochrome c release from mitochondria [352]. According to Casley 
and co-worker, addition of Aβ to isolated rat brain mitochondria inhibited 
respiration and CcOX activity [366]. This is consistent with studies in 
neuroblastoma SHSY-5Y cells [367] and Tg2576 mice [346], both overexpressing 
APP. It was observed that also patients with AD showed impaired cytochrome c 
oxidase activity in the central nervous system. In 1990, Parker et al. reported 
about 50% reduction of CcOX activity in platelet mitochondria isolated from 
patients with AD [368]. Depressed CcOX activity has also been shown in 
homogenates of various brain regions, including frontal (−26%), temporal (−17%) 
and parietal (−16%) cortices as reported by Kish et al. [369]. Recently Bobba and 
co-worker observed that Aβ42 inhibits mitochondrial respiration and that this 
inhibition is accomplished by efficiently blocking the activity of respiratory 
Complexes I and IV [370]. This is maybe due to a direct interaction of Aβ with 
complexes IV and complex I, documented in vitro or to an increase in RONS 
production [370]. Several studies have demonstrated decreased pyruvate 
dehydrogenase (PDH) [371, 372] and α-ketoglutarate dehydrogenase (KGDH) 
activity [373] in the temporal and parietal cortex of AD brains. In vitro binding 
studies demonstrated that Aβ interact with the mitochondrial matrix protein, 
amyloid-beta-binding alcohol dehydrogenase (ABAD), leading to mitochondrial 
dysfunction [313]. Aβ interactions with cyclophilin D, a suggested subunit of the 
permeability transition pore, may also contribute to similar mitochondrial 
dysfunctions and exacerbate cell death [374]. Aβ influences the fission/fusion 
dynamic by altering the fission/fusion-related protein levels, increasing the 
expression of mitochondria fission genes and decreasing that of fusion genes. The 
increased fission gene expression prompted by Aβ alters mitochondrial 
morphology through fragmentation, resulting in a significantly increased number 
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of mitochondria [375, 376]. Intramitochondrial Aβ is able to perturb 
mitochondrial function in several ways by directly influencing extracellular 
transport chain complex activities, impairing mitochondrial dynamics, or 
disturbing calcium storage, thus increasing apoptotic pathways.  
Despite all these observations, the presence of Aβ into the mitochondria is still 
debated and the mechanisms by which Aβ  induces mitochondrial impairment are 
still unknown. An hypothesis is that Aβ  may be caused mitochondrial 
dysfunction by the formation of pore-like structures in the mitochondrial 
membranes. Alternatively, Aβ may generate free radicals during aggregation and 
therefore cause oxidative damage to mitochondrial membranes and proteins. In 
this frame, it is worth considering that mitochondria are the leading sites for 
RONS production, and that nitric oxide, as part of them, has been proposed to 
play a major role in neurodegenerative disease, AD included.  
1.4.4 Alzheimer’s disease and NO 
Numerous reports demonstrate that AD is characterized by a pathological rise of 
RONS concentrations [377]. Markers of lipid peroxidation, nucleic acid damage 
or protein modification were found to be upregulated in brains of AD patients (3-
nitrotyrosine (3-NT) or protein carbonyls). Importantly, increased oxidative and 
nitrosative damage seems to be an early event in the process of neurodegeneration 
associated with AD [378-380]. One simple explanation of increased nitro-
oxidative stress in AD is directly linked to Aβ toxicity. It is well known that the 
accumulation of Aβ in plaques as well as AβOs may produce sequential 
inflammatory/oxidative events and excitotoxicity, causing neurodegeneration and 
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cognitive impairment [311, 381, 382]. On one side, the potential of Aβ to generate 
free radicals has been observed by in vitro experiments, on the other side, 
however, other experimental models showed that the nitro-oxidative stress seems 
to precede the Aβ plaques formation [383]. There are also data showing that the 
oxidative stress can actually alter the metabolism of both the Aβ precursor protein 
and tau, thus promoting formation of plaques and tangles [384-386]. An apparent 
hallmark of AD is the decreased brain energy metabolism, attributed to 
mitochondrial dysfunction and the increased RONS production. Last but not least, 
inflammatory processes seem to be part of AD pathology. In vitro experiments 
have shown that Aβ can activate microglia [387]. Glia cells are present in the Aβ 
plaques and in their surroundings [354, 388]. Activation of microglia is associated 
with production of RONS and potentially leads to damage of the neighbouring 
neurons, further supporting the idea that NO may play a critical role in the 
pathogenesis of AD [354, 389]. Consistently, several studies have shown that the 
NOS expression is altered in AD and it has been suggested that the iNOS plays a 
role in the plaques and neurofibrillary tangles formation [390]. In this line, it has 
been shown that the NO overproduction, in fact, occurs much earlier than amyloid 
deposition. Luth and co-worker analyzed the expression of all NOS isoforms in 
AD and control brains; they also compared the NOS(s) localization with the 
distribution of nitrotyrosine [391]. In their study, nitrotyrosine was detected in AD 
neurons, astrocytes, and blood vessel. Aberrant expression of nNOS in cortical  
pyramidal cells was highly co-localized with nitrotyrosine. Furthermore, iNOS 
and eNOS were highly expressed in AD astrocytes where a double 
immunolabeling revealed that iNOS and eNOS were co-localized with 
nitrotyrosine. The increased expression of NOS in astrocytes and neurons 
contribute to the formation of peroxynitrite and to the generation of nitrotyrosine 
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[391]. The iNOS expression is associated with immune activation and thus is 
observed mainly in the reactive astrocytes and microglia surrounding the Aβ 
deposits. The presence of L-arginine in astrocytes in vivo suggests that glia may 
store L-arginine for NO production in the brain [42, 392, 393]. The eNOS 
immunoreactivity has been localised around the blood vessels of AD patients. The 
data of Colton and co-author support a role for nNOS neurons in AD [394]. Cetin 
et al. [395] found a decrease of nNOS expression in the hippocampus of Aβ42 
injected aged rats, while Aβ42 injected young adult rats showed a significant 
increase of the nNOS expression. The authors hypothesize that the damaging 
effects of low physiological concentrations of Aβ might initially, in young adults, 
be overcome at least by an adaptive response. However, when age related 
secondary stress occurs, mitochondrial impairment might lead to the induction of 
cell death. Under this condition a decrease in nNOS expression was observed 
[395]. The impairment of the nNOS, induces loss of the NO-dependent neuronal 
functions, such as memory [78]. It has also been observed that aggregated Aβ 
inhibits the NO signaling pathway and suppresses the protective effects of 
endogenous NO in the brain [396]. In this respect the NO produced by the 
neuronal NOS (nNOS) and the endothelial NOS (eNOS) plays a protective role 
against Aβ-induced neuronal cell death, cerebrovascular dysfunction, and cerebral 
amyloid angiopathy [397]. 
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2. AIM 
This work has been developed following two different experimental approaches, 
sharing the common purpose of investigating the putative role of nitric oxide 
(NO) in the bioenergetic context of different cell lines. 
In one set of experiments, carried out using human keratinocytes (HaCaT cells), a 
new role of melatonin related to the NO signaling has been envisaged and studied. 
In a second set of experiments, the mitochondrial functional state of a validated 
cell model of Alzheimer’s disease (AD) has been investigated and related to the 
NO chemistry.  
         NO is implicated in the control of both the mitochondrial oxidative 
phosphorylation and the sleep/wake cycle; the latter is compatible with the night 
accumulation of NO and its oxidation products, nitrite and nitrate.  
In this work it has been suggested that NO could be part of the complex signaling 
pathway triggered by melatonin, the main regulator of the circadian rhythm, that, 
through modulation of the NO synthase activity, could increase the cell NO 
bioavailability, with relevant effects on mitochondria. 
       Beside these physiological effects, NO has been recently reported to be 
implicated in neurodegenerations, such as AD, thus a link between NO and 
mitochondrial failure has been envisaged. 
The bioenergetics of melatonin-treated and AD cells has been investigated with a 
particular attention devoted to measure the NOSs expression, as determined by 
Real-Time PCR and Western Blot analysis; the nitrite and nitrate accumulation in 
the cell culture medium was also assessed. The mitochondrial membrane potential 
was investigated by measuring the accumulation of the fluorescent probe JC-1 in 
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the mitochondrial matrix and the mitochondrial respiration was evaluated using 
intact and permeabilized cells. Cell bioenergetic changes were further explored by 
measuring the production of ATP and lactate. 
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3. MATERIALS AND METHODS 
3.1 Cell cultures 
Human keratinocyte (HaCaT) cell line, were grown at 37 °C, 5% CO2, 95% air in 
DMEM (Dulbecco’s modified Eagle’s) medium containing 4.5 g/L glucose, 10% 
FBS, supplemented with 2 mM L-glutamine and 50 µg/ml gentamicin in 75-cm2 
flasks, 25-cm2 flasks or multiwall plates. The day before the experiments, cells 
were grown in DMEM containing 1 g/L glucose and 2 mM L-glutamine (w/o 
FBS, phenol red and gentamicin).  
Chinese hamster ovary (CHO) cells, were grown in Ham’s F12 media 
supplemented with 2 mM L-glutamine, 10% FBS and 1% penicillin/streptomycin. 
The 7WD4 and 7PA2 (kindly provided by Dr. Denis Selkoe, Harvard Medical 
School, Boston, thanks to Prof. Antonino Cattaneo, European Brain Research 
Institute (EBRI), Rome) are CHO cell lines stably expressing human wtAPP751 
(7WD4 cells) and APP751 harboring mutation V717F (7PA2 cells). The 7WD4 
and 7PA2 cells were cultured in Ham’s F12 containing 10% FBS, 2 mM L-
glutamine, 1% penicillin/streptomycin and G418 for maintaining selection of 
hAPP stable transfect. Before the experiments, 7WD4 and 7PA2 cells were plated 
without G418 antibiotic in order to be in the same culture conditions as control 
CHO cells. 
3.2 Citrate Synthase 
Cells (1x106), harvested by trypsinization and centrifugation (1.000 x g for 5 min 
at 20 °C), were lysed by CelLyticTMMT Cell Lysis Reagent in the presence of the 
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Protease Inhibitor Cocktail and centrifuged at 20.000 x g for 10 min. Cell lysates 
were assayed for the determination of citrate synthase activity [398]. Citrate 
synthase is localized in the mitochondrial matrix and is commonly used as a 
quantitative marker enzyme for the content of intact mitochondria. Citrate 
synthase catalyzes the reaction between acetyl coenzyme A (acetyl CoA) and 
oxaloacetic acid (OAA) to form citric acid. The hydrolysis of the thioester of 
acetyl CoA results in the formation of CoA with a thiol group (CoA-SH). The 
thiol reacts with the DTNB in the reaction mixture to form 5-thio-2-nitrobenzoic 
acid (TNB). This yellow product (TNB) is observed spectrophotometrically by 
measuring absorbance at 412 nm. 
3.3 Melatonin Determination 
The presence of melatonin in living cells was evaluated by immunoassay using 
the ‘‘Direct saliva Melatonin ELISA kit’’ (BÜHLMANN), as adapted to cell 
lysates. HaCaT cells (3x106) were incubated with melatonin (1 nM) for 1 h and 5 
h. After incubation, both melatonin-treated and control cells were harvested, 
resuspended (at 106/mL density), and lysed by CelLyticTMMT Cell Lysis Reagent 
in the presence of the Protease Inhibitor Cocktail. The cell lysates were incubated 
for 15 minutes on a shaker and centrifuged at 20.000 x g for 10 minutes. Aliquots 
of lysates were loaded on a plate containing anti-melatonin polyclonal antibody 
for enzyme-linked immunosorbent assay (ELISA). After overnight incubation 
(16-20 hours), the melatonin contained in the lysates and in the calibrators 
competed for the binding sites of a highly specific antibody with biotinylated 
melatonin added during following 3 hours incubation. After suitable washing, the 
enzyme label, streptavidin conjugated to horseradish peroxidase (HRP) was 
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added, which binds during further 60 minutes incubation to the melatonin-biotin-
antibody complexes captured on the coated wells. Unbound enzyme label was 
then removed by washing and TMB substrate (tetramethylbenzidine) was added to 
the wells. In a fourth 30 minutes incubation step, a chromophore was formed in 
inverse proportion to the amount of melatonin present in the sample. The colour 
turned from blue to yellow after the addition of an acidic stop solution and was 
observed spectrophotometrically by measuring absorbance at 450 nm. 
3.4 Real Time PCR 
Quantitative Real Time Polymerase Chain Reaction (QRT-PCR) was carried out 
in HaCaT cells, incubated 6 h with increasing amount of melatonin or at different 
time with melatonin 1 nM, using specific oligonucleotide primers in order to 
identify and quantify the different Nitric Oxide Synthase (NOS) isoforms. After 
incubation, cells were harvested by trypsinization and centrifugation (1000 x g for 
5 min at 20°C), washed twice with Hank’s buffer and counted. Cells (1x106) were 
lysed by Trizol reagent and total RNA was isolated by phenol-chloroform 
extraction [399]. RNA purity was measured using a spectrophotometer by 
determining the ratio of absorbance at 260 nm to the absorbance at 280 nm 
(A260/A280). Pure RNA shows an A260/A280 ratio of 1.9 - 2.1 in 10 mM Tris at pH 
7.5. Contamination by phenol or urea will show absorbance at 230 nm or 270 nm, 
respectively. Protein contaminants have a high absorbance at 280 nm and 
therefore produce a low A260/A280 ratio. Absorbancies at 235 nm indicates the 
presence of contaminants. RNA quality was assayed by gel electrophoresis, which 
allows to visualize discrete intact ribosomal bands and determine the degree of 
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RNA degradation. High-quality total RNA was indicated by sharp bands 
corresponding to 28S and 18S rRNA, at a ratio of approximately 2:1 (Fig. 11).  
 
CTR 0 .5nM 1nM 10nM 100nM 1 µ M
rRNA 28S
rRNA 18S
 
 
Fig. 11: Electrophoretic analysis of total RNA extracted from HaCaT cells. HaCaT cells were 
incubated for 6 h at increasing melatonin concentrations. 
 
1 µg of total RNA was used as a template for the cDNA synthesis. The reverse 
transcription reaction was performed using Side-StepTM II QRT-PCR cDNA 
Synthesis Kit (Stratagene). QRT-PCR was performed using primers designed by 
BioRad Laboratories (Software Beacon Designer) and purchased by PRIMM. β-
actin gene (PRIMM) was used for normalization. 
 
nNOS  (NOS1) 
Forward :  5’ GCGGTTCTCTATAGCTTCCAGA 3’ 
Reverse :   5’ CCATGTGCTTAATGAAGGACTCG 3’ 
eNOS  (NOS3) 
Forward : 5’ GCCGTGCTGCACAGTTACC 3’ 
Reverse :  5’ GCTCATTCTCCAGGTGCTTCAT 3’ 
β-actina 
Forward :  5’ GCGAGAAGATGACCCAGATC 3’ 
Reverse :  5’ GGATAGCACAGCCTGGATAG 3’  
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SYBR Green  has been used as intercalating-dye which is able to bind double-
stranded DNA and upon excitation to emit light (excitation = 470 nm; emission = 
510 nm). Thus, as a PCR product accumulates, fluorescence increases. This 
method require a special thermocycler equipped with a sensitive camera 
(Stratagene Mx3005p System, Agilent Technologies) that monitors the 
fluorescence in each well of the 96-well plate at frequent intervals during the PCR 
reaction. The cDNAs were amplified using 45 cycles consisting of denaturation 
step (95 °C for 5 min) and amplification step (95 °C for 10 sec, 55 °C for 30 sec). 
A normal amplification curve from a dilution series of a sample is shown in Fig. 
12a. Amplification plots are created when the fluorescent signal from each sample 
is plotted against cycle number; therefore, amplification plots represent the 
accumulation of product over the duration of the real-time PCR experiment. The 
initial PCR cycles produce low fluorescent signals that cannot be detected by the 
CCD camera. The linear portion of each curve is in the exponential phase of PCR, 
where the amount of product, and therefore the signal, doubles after each cycle. 
The top portion of the curves shows minimal signal increase, as PCR slows due to 
the depletion of reaction components, such as primers and dNTPs. Melting curve 
analysis was performed at the end of every run to ensure a single amplified 
product for each reaction. During a Melting Curve Analysis, all products 
generated during the PCR amplification reaction were melted at 95 °C, then 
annealed at 55 °C and subjected to gradual increases in temperature. The results is 
a plot of raw fluorescence data units, R, versus temperature. Fig. 12b shows the 
melt data as the negative first derivative of raw fluorescence, R’(T), plotted 
against an increase in temperature. In this view, every peak in the curve indicates 
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a specific product melting. Most QPCR products will melt somewhere in the 
range of 70 - 90 °C. 
 
 
 
Fig. 12: a) Relative fluorescence versus Cycle number. Amplification plots are created when the 
fluorescent signal from each sample is plotted against  cycle number; therefore, amplification plots 
represent the accumulation of product over the duration of the real-time PCR experiment. Real-
time PCR amplification plot. Fluorescent signal is plotted against cycle number. b) The -∆F/∆T 
(change in fluorescence/change in temperature) is plotted against temperature to obtain a clear 
view of the melting dynamics.  
 
Ideally, a single peak within this temperature range is observed and the melting 
temperature should be the same in all the reactions where the same sample is 
amplified. If any secondary peaks are seen on the peak of interest, this indicates 
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that something other than the gene of interest is present among the reaction 
products. The strategies employed to quantify the results obtained by QRT-PCR is 
termed comparative threshold (Ct = cycle threshold) method. This involves 
comparing the Ct values of the samples of interest with a control or calibrator 
such as a non-treated sample. The Ct value is the cycle number at which the 
fluorescence generated within a reaction crosses the fluorescence threshold, a 
fluorescent signal significantly above the background fluorescence. At the 
threshold cycle, a detectable amount of amplicon product has been generated 
during the early exponential phase of the reaction. The threshold cycle is inversely 
proportional to the original relative expression level of the gene of interest. The Ct 
values of both the calibrator and the samples of interest are normalized to the 
endogenous housekeeping, β-actin. The comparative Ct method is also known as 
the 2-(∆)(∆)Ct method, where 
(∆)(∆)Ct = (∆)Ctsample - (∆)Ctreference 
Here, (∆)Ctsample is the Ct value for any sample normalized to the endogenous 
housekeeping gene and (∆)Ctreference is the Ct value for the control also normalized 
to the endogenous housekeeping gene. 
3.5 Western Blot 
HaCaT cells, grown overnight in DMEM containing 1 g/L glucose, 2 mM L-
glutamine without FBS, were incubated with melatonin (1 nM) at different time. 
After melatonin incubation, HaCaT cells were harvested by trypsinization and 
centrifugation (1000 x g for 5 min at 25°C), washed twice with Hank’s buffer and 
lysed with CelLytic™MT Cell Lysis Reagent in the presence of protease 
inhibitors. The cell lysates were incubated for 15 minutes on a shaker and 
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centrifuged at 20.000 x g for 10 min. The protein concentration was determined 
by Bradford assay [400]. Samples were run on gel electrophoresis, 10 % SDS-
PAGE gels in order to obtain protein separation. 20 µg of total protein from cell 
lysate was loaded into wells in the gel. One lane was reserved for the marker 
(Invitrogen, SeeBlue® Plus2 prestained standard), a commercially available 
mixture of proteins having defined molecular weights. SDS-PAGE (SDS 
polyacrylamide gel electrophoresis) maintains polypeptides in a denatured state 
once they have been treated with strong reducing agents, in these case 
dithiothreitol (DTT) to remove secondary and tertiary structure and thus allows 
separation of proteins by their molecular weight. The gel was run at 90 V through 
the stacking part of the gel and the volts were turned up to 150 V after the proteins 
have gone through the stack and are migrating through the resolving gel. 
Following electrophoresis, the protein was transferred on nitrocellulose 
membranes (Whatman, GE Halthcare UK) for 1 h at 100 mA. Blocking of non-
specific binding was achieved by placing the membrane in PBS with 0.1 % tween 
and 3 % BSA for 2 h at room temperature. After blocking, the membrane was 
incubated overnight at 4°C with primary rabbit polyclonal anti-nNOS antibodies 
(from BD Transduction Laboratories); α-tubulin was used as the reference. A 
secondary ECL TM anti-rabbit antibody HRP (Jackson) was thereafter incubated 
1 h at 25°C. Washing steps (consisting to washes of PBS, 0.1 % Tween, 5 minutes 
each) were necessary to remove unbound reagents and reduce background. The 
imagine was determined for chemiluminescence (Amersham, GE Halthcare UK). 
Densitometric analysis was carried out by the KODAK 1D Image Analysis 
Software (Eastman Kodak Company).  
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3.6 Nitrate / Nitrite (NOX) determination 
The total concentration of nitrite and nitrate (NOX) is used as a quantitative 
measure of NO production. Accumulation of the NOX in the culture medium of 
HaCaT cells (~ 2.5 × 105 cells/mL), grown over night in DMEM 1 g/L glucose 
(without FBS and phenol red), was measured after 6 h and 8 h exposure to 
melatonin at the given concentrations or at different times of incubation with 1 
nM melatonin. In the case of CHO and 7PA2 cells, the NOX content in the 
supernatants was evaluated after 4 h of accumulation. Incubations of cells for 
NOX measurements were performed in serum-free DMEM without phenol red, 
because both FBS and phenol red can cause a significant reduction in the intensity 
of the fluorescence. After incubation, the cell supernatants were centrifuged at 
4°C, 1000 x g for 10 min and the NOX content was determined fluorometrically 
(Nitrate/Nitrite Fluorometric Assay Kit, Cayman Chemical Co.). Nitrate/Nitrite 
Fluorometric Assay Kit provides an accurate and convenient measurement of total 
nitrate/nitrite concentration in a simple two-step process. In the first step nitrate is 
converted to nitrite by nitrate reductase:  
NO3- + e- + 2H+   →  NO2- + H2O 
In the second step, nitrite reacts with the fluorescent probe DAN (2, 3-
diaminonaphthalene). NaOH enhances the detection of the fluorescent product, 
1(H)-naphthotriazole (NAT) (Fig. 13).  
 
 
 
Fig. 13: Reaction of 2,3-Diaminonaphthalene (DAN) with NO2-. 
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The fluorescent intensity is proportional to the total nitric oxide production and 
was measured at the Fluorescence Plate Reader VICTORTM Multilabel Counter 
(Perkin Elmer) using an excitation wavelength of 375 nm and an emission 
wavelength of 420 nm. 
The NOX concentrations were determined using the following equation: 
 
3.7 Mitochondrial membrane potential measurement 
The mitochondrial membrane potential was measured exploiting the accumulation 
of the cationic fluorescent probe JC-1 (Fig. 14) into the mitochondrial negatively 
charged matrix [401]. The fluorescence emission of JC-1 depends both on its 
concentration and on the excitation wavelength. 
 
 
 
Fig. 14: Structure of JC-1 (5,5’,6,6’-tetrachloro-1,1’,3,3’ tetraethylbenzimidazolylcarbocyanine 
iodide).  
 
Upon exciting at 490 nm, JC-1 monomers display a cytoplasmic fluorescence 
emission centered at 537 nm (green band). Above a critical concentration, better 
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reached at high mitochondrial membrane potential value (∆Ψ ≥ 200 mV), JC-1 
aggregates are formed in the mitochondria, characterised by an intense emission 
band centred at 590 nm (red band) (Fig. 15).  
 
 
Fig. 15: Excitation and Emission Spectra of JC-1. JC-1 is a cationic dye that exhibit a potential-
dependent accumulation in mitochondria, indicated by a fluorescence emission shift from green 
(~525 nm) to red (~590 nm). The potential-sensitive colour shift is due to concentration-dependent 
formation of red fluorescent J-aggregates. 
 
Before the fluorescence measurement, HaCaT cells, grown at the semi-confluence 
in flask of 25 cm2 and incubated 6 h in the presence or absence of melatonin (0.5 - 
100 nM), are washed twice with PBS (containing 8 g/L NaCl, 0.2 g/L KCl, 1.11 
g/L Na2HPO4, 0.2 g/L KH2PO4) and pre-incubated for 1 h at 37 °C in a 
physiological low-K+ buffer (containing 137 mM NaCl, 3.6 mM KCl, 1.8 mM 
CaCl2, 0.5 mM MgCl2, 4 mM Hepes and 1 x mixed aminoacids from GIBCO plus 
0.5 mM L-arginine at pH 7.2) in the presence of melatonin and in the absence of 
glucose to stimulate the oxidative phosphorilation (OXPHOS). For the 
experiment, cells were trypsinized, gently centrifuged at 1100 x g, for 5 min at 20 
°C, and resuspended in high-K+ buffer (containing 137 mM KCl, 3.6 mM NaCl, 
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1.8 mM CaCl2, 0.5 mM MgCl2, 4 mM Hepes at pH 7.2), to obtain a cell 
suspension of 1x106 cells/ml. In the case of CHO and 7PA2 cells, a similar 
condition was used to measure ∆Ψ, with the only difference consisting in the use 
of DMEM (w/o glucose) as pre-incubation buffer, due to a high sensitivity of 
these cells to K+ buffer. For the same reason, the experiment were carried out in 
DMEM (containing glucose, 1 g/L) without phenol red, to obtain a cell suspension 
of 3x106 cells/ml. The kinetics of JC-1 accumulation was followed in the presence 
of ouabain 2 µM in order to dissipate the plasma membrane potential, possibly 
abolishing any aspecific cytoplasmatic fluorescence. Accumulation of the JC-1 
aggregates into mitochondria was started by adding 0.6 µM nigericin to the cells, 
pre-mixed with the 0.3 µM JC-1. Nigericin is an electroneutral K+/H+ antiporter 
ionophore which converts the ∆pH component of ∆µH+ into the electrical 
membrane potential gradient ∆Ψ, allowing full expression of mitochondrial ∆µH+ 
as ∆Ψ [402] (Fig. 16a).  
 
 
 
Fig. 16: Structure of nigericin (a) and valinomycin (b).   
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After addition of nigericin, the fluorescence level reached a maximum within 
approximately 60 min; thereafter, the fluorescence signal was rapidly dissipated 
by 0.2 µM valinomycin, a mobile carrier ionophore which catalyses the electrical 
uniport of K+ (Fig. 16b). The kinetics of JC-1 accumulation was measured in 24-
well black plates using the Fluorescence Plate Reader VICTORTM Multilabel 
Counter (Perkin Elmer); the excitation filter was selected at 490 nm and the 
emission filters at 595 nm, to detect the red aggregates of the probe JC-1. 
3.8 Polarographic measurements  
Oxygen consumption was measured with the OROBOROS Oxygraph 2k (Fig. 17) 
(Oroboros Instruments). The software DatLab (Oroboros, Innsbruck, Austria) was 
used for data acquisition (1 s time intervals) and analysis, including calculation of 
the time derivative of oxygen concentration normalized per mg of protein (O2 flux 
per mass: pmol sec-1 mg-1), signal deconvolution dependent on the response time 
(τ) of the oxygen sensor and correction for instrumental background oxygen flux 
[403, 404]. In all applications the chamber volume is 1.5 ml. The large inner 
diameter of the chamber (16 mm) provides space for additional electrodes, light 
guide and mechanical transducer. Each chamber is equipped with a polarographic 
oxygen sensor (POS) with a large cathode (2-mm diameter) that increases the 
sensitivity and signal-to-noise ratio and decreases the signal drift at zero oxygen. 
Gas-aqueous phase boundaries must be avoided to exclude uncontrolled oxygen 
gradients within the measuring system. Measurements of oxygen back-diffusion 
and mathematical correction for background were carried out to perform high 
accuracy of flux. 
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3.8.1 Polarographic oxygen sensor (POS)  
In the O2 Clark-type electrode, the probe is a platinum wire coated with Ag/AgCl, 
serving as reference electrode. The selectivity towards the specific gas is achieved 
by i) a gas-permeable hydrophobic membrane isolating the probe from the other 
redox-active non-gaseus species which might be present in the solution and ii) the 
polarization voltage applied. This is – 0.67 V for O2 (1/2 O2 + 2 e- + 2 H+  H2O).  
 
 
 
Fig. 17: a) The OROBOROS Oxygraph 2k with the Titration-Injection microPump (Tip-2k) on 
top and the Integrated Suction System (ISS) on the right. b) Inside view of the OROBOROS 
Oxygraph 2k instruments. A, left: external of chamber; B, right: internal of chamber.  
 
The oxygen electrode was calibrated by recording the signal in air-equilibrated 
buffer (corresponding to [O2] in the range 200-300 µM, calculated from the 
solubility of the gas in the experimental conditions used) and subtracting the 
signal measured upon addition of excess sodium dithionite ([O2] = 0). 
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3.8.2 Air and oxygen calibration 
The oxygen sensors were calibrated by a two-point calibration, routinely achieved 
at air saturation and zero oxygen concentration. Accordingly, static calibration 
involves the determination of the constant signal of the polarographic oxygen 
sensor at 0 % and 100 % air saturation (R0 and R1, respectively) under the 
particular experimental conditions (temperature, signal amplification by electronic 
gain, polarization voltage, stirring speed, medium). Air saturation was achieved 
by stirring the medium without sample in the chambers in contact with air, until 
the oxygen signal (the slope expressed as pmol sec-1 ml-1) becomes constant (in 
about 20 min). After stabilization of the oxygen signal, R1 must be < 10 Volts. 
Zero oxygen calibration was achieved by allowing complete oxygen depletion or 
alternatively by use a freshly prepared a 2-5 % solution of Na-dithionite (sodium 
hydrosulfite: Na2S2O4) in water. The instrumental background test is necessary for 
a calibration of the O2k chamber performance. The chamber was closed without 
sample and after stabilization for 10 min, oxygen consumption was obtained by 
the polarographic oxygen sensor at air saturation and it was indicated as J°1 (the 
uncorrected oxygen slope expressed as pmol sec-1 ml-1). In the next steps the 
oxygen concentration was reduced by nitrogen gas. At progressively lower steps 
of oxygen concentration, the oxygen consumption by the sensor decreased 
linearly and the effect of oxygen backdifussion was finally apparent as a positive 
slope or negative flux. The linear dependence of background oxygen flux from 
oxygen concentration is described by the equation with slope b° and intercept a°: 
JO2° = b° cO2 + a°    (Y=b°x + a°) 
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The linear regression was automatically displayed in the DatLab4-Excel file “O2k-
Background.xls”, plotting background oxygen flux as a function of oxygen flux as 
a function of oxygen concentration with intercept a° and slope b° (Fig. 18).  
 
 
Fig. 18: O2k-Background. Oxygen calibration in Hank’s buffer containing 5.5 mM glucose. The 
graphs show oxygen flux as a function of oxygen concentration, with the linear regression 
parameters.  
 
These values were used for on-line instrumental background correction of flux 
during respirometric experiments in the corresponding O2k-chambers.  
3.8.3 Measurements of oxygen consumption in intact cells 
HaCaT cells, grown overnight in an antibiotic/FBS-free DMEM medium, were 
incubated 8 h with increasing melatonin concentrations (0.5, 1, 10, 100 nM); 
when required, the nNOS inhibitor, 7-nitroindazole (7N), was added (500 nM) 30 
min before the measurement. For the assay, cells were harvested with trypsin–
EDTA, washed twice by centrifugation at 1000 x g for 5 min at 20°C through 
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Hank’s medium, containing 5.5 mM glucose and resuspended in Hank’s medium, 
containing 5.5 mM glucose at a density of 3,3 × 106 cells / ml.  
CHO and 7PA2 cells (3,3×106 cells/ml) were resuspended in DMEM, containing 
glucose 1 g/L Cellular oxygen consumption was evaluated using high resolution 
respirometry. Value were normalized by protein determination [400]. 
3.8.4 Measurements of oxygen consumption in permeabilized cells 
HaCaT cells, grown over night in 1 g/L glucose DMEM (w/o FBS and phenol 
red), were incubated 8 h in the presence and absence of 1 nM melatonin. CHO 
and 7PA2 cells were cultured in 75-cm2 flasks in Ham’s F12 containing 10 % 
FBS, 2 mM L-glutamine, 1 % penicillin/streptomycin without G418. Before the 
experiments, cells were washed twice with PBS, harvested with 0.5 % trypsin-
EDTA, gently centrifuged at 1100 x g for 5 min at 20 °C, washed with respiration 
medium, centrifuged at 1100 x g for 5 min at 20 °C and resuspended in respiration 
medium. Cell density was determined by cell count and cell viability was 
evaluated by trypan blue exclusion test. Total protein was measured by Bradford 
assay. The respiration medium was added to the oxygraph chambers about ten 
minute before the measurements and was equilibrated with atmospheric oxygen 
and the required experimental temperature (37 °C). Cell suspension was added to 
the oxygraph chambers containing respiration medium to a final cell density of 
3.3 x 106 cells / ml and the system was equilibrated again for 5 min.  The 
respiration medium consists of: 3 mM MgCl2 x 6 H2O (0.61 g/L), 20 mM taurine 
(2.502 g/L), 10 mM KH2PO4 (1.361 g/L), 20 mM HEPES (4.77 g/L), 1 g/L BSA, 
110mM mannitol (20.04 g/L), 0.3mM dithiothreitol (0.046 g/L), pH 7.1, adjusted 
with 5 N KOH. The respiration medium was supplemented with 0.5 mM EGTA 
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(0.19 g/L) in respiration measurements of CHO and 7PA2 cells. EGTA was used 
to create the appropriate free concentration of Ca2+ in the physiological range. In 
addition, EGTA chelates contaminating heavy metals toxic for mitochondria. 
EGTA wasn’t used in the experiments involving melatonin. EGTA may mask the 
action of melatonin because of its higher affinity for calcium ions. Respiration 
was assayed and evaluated in cells permeabilized with digitonine. Digitonin is a 
Cholesterol-complex forming agent that interact with cholesterol molecules of the 
plasma membrane (the polar heads of the cholesterol are associated with the polar 
heads of the phospholipids). The interaction induces a loss of membrane integrity 
(permeabilization), so that the barrier between the intracellular space and 
surrounding medium disappears. The cholesterol content of intracellular 
organelles like mitochondria is considerably lower and so the optimal digitonin 
concentration that doesn’t disrupt these organelles but its action is confined to 
outer cell membrane needs to be experimentally determinated. The optimal 
digitonine concentration and the incubation time was determined according to 
[405]. Briefly, the digitonine titration curve for 3.3 x 106 cells/ml was performed 
in mitochondrial medium, in the presence of 10 mM succinate, 0.5 µM rotenone 
and 1 mM ADP (Fig. 19). Time intervals between titrations were 12-14 min up to 
3 µg cm-3 and 4-5 min at higher digitonin concentrations. Putative membrane 
damage produced by digitonin was also evaluated, by independently assaying the 
onset of sensitivity of cell respiration to externally added cytochrome c2+. The 
optimal digitonin concentration obtained as described was added to cell 
suspension using a 25-µl Hamilton microsyringe and was incubated for about 10 
min (at 37 °C). Typically, after addition of digitonin, the cell respiration rate 
markedly declines for 5–7 min. The lower rate of endogenous cellular respiration 
in the absence of mitochondrial substrates (e.g., pyruvate + malate) is indicative 
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of the plasma membrane permeabilization, followed by the leakage and dilution of 
intracellular metabolites when complete cell permeabilization has been achieved. 
Digitonin used for permeabilization does not influence mitochondrial respiration 
and can be present in the medium during the entire respirometric run. 
 
 
 
Fig. 19: Sequential representation of the mitochondrial respiratory chain. Experimental design of 
oxygraphic titration, using specific substrate and inhibitors. Cx I-IV: mitochondrial complex I-IV. 
Rot: rotenone (0.5 µM, inhibitor of Cx I), Ant A: antimycin A (5 µM, inhibitor of Cx III). Pyr/Mal: 
Pyruvate + Malate (8.8 mM and 4.4 mM respectively); Succ: succinate (10 mM); Asc/TMPD: 
ascorbate + TMPD (2 mM and 0.5 mM respectively, reductants of CxIV); Q: ubiquinol, Cyt c: 
cytochrome c (modified from Krako et al. 2013).  
 
The contribution of the respiratory complexes to cell respiration was also 
evaluated according to Kuznetsov et al. with minor modifications (fig. 19) [406]: 
- 8.8 mM pyruvate and 4.4 mM malate were added, using a 25-µl Hamilton 
microsyringe, to record resting complex I-supported respiration, without ADP. 
- ADP was added, using a 25-µl Hamilton microsyringe,  to obtain a final 
(saturating) concentration of 2 mM for maximal mitochondrial respiration (state 
3). The rate of state 3 respiration at saturating ADP concentrations should be 
stable for at least 10–15 min. 
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- 0.5 µM rotenone, a specific inhibitor of complex I, was added to inhibit complex 
I. Respiration should be almost completely inhibited. 
- 10 mM succinate was added to induce complex II-supported respiration. 
- 5 µM antimycin A, a specific inhibitor of complex III was added to inhibit 
Complex III. Inhibition of respiration should be similar to that seen after the 
addition of rotenone. 
- Complex IV respiration was activated by adding 0.5 mM TMPD and 2 mM 
ascorbate, artificial substrates specific for this complex. 
- 10 mM cytochrome c was added to show the intactness of the outer 
mitochondrial membrane.  
3.9 ATP measurements 
The cell adenosine-5’-triphosphate (ATP) concentration was quantified by 
chemiluminescence, under stationary conditions or kinetically by following the 
rate of ATP production.  
Depending on the experiment, the stationary ATP measurement were performed 
using HaCaT cells, before and after treatment with melatonin 1 nM for 6 h and 
seeded at a density of ~ 5 x 105 cells / ml in 96-well plates. A similar protocol was 
used with CHO and 7PA2 cells. Cells were suspended for 4 h in PBS containing 2 
mM L-glutamine, in the presence or absence of 11 mM glucose; when necessary, 
2.5 µg/ml oligomycin was added over the last 1.5 h incubation. The starvation of 
glucose is necessary to avoid the glycolytic-driven metabolism and the ATP- 
synthase inhibitor oligomycin to inhibit OXPHOS. 
The rate of ATP production was evaluated after cell membrane permeabilization 
[407]. After incubation with 1 nM melatonin for 6 h, HaCaT cells were harvested 
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by trypsinization and centrifugation (1000 x g for 5 min at 20 °C), washed with 
PBS and resuspended with PBS at 3x106/ml cells density. In order to permeabilize 
cells and minimize ATP synthesis by biochemical pathways other than oxidative 
phosphorylation, HaCaT cells (3×106 cells/ml) were incubated for 20 min at room 
temperature with 60 µg/ml digitonin, 2 mM iodoacetamide, and the adenylate 
kinase inhibitor, P1,P5-di(adenosine-5’) pentaphosphate pentasodium salt (25 
µM), in 10 mM Tris/HCl (pH 7.4), 100 mM KCl, 5 mM KH2PO4, 1 mM EGTA, 3 
mM EDTA and 2 mM MgCl2. Complex II driven ATP synthesis was induced by 
adding to the permeabilized cells, succinate (20 mM) and ADP (0.5 mM), in the 
presence of rotenone (4 µM). The reaction was carried out at 30 °C and stopped 
after 5 min by the addition of 80 % DMSO. A reference sample was assayed in 
the absence of succinate and in the presence of antimycine A (18 µM) and 
oligomycin (2 µM).  
Synthesized ATP was measured using the ATPlite1step kit (Perkin Elmer). The 
assay is based on the detection of light generated by the reaction of ATP with 
luciferase and D-luciferin. The reaction is catalyzed by the enzyme luciferase 
obtained from the firefly (Photinus pyralis). The MgATP2- converts the luciferin 
into a form which is capable of being catalytically oxidized by the luciferase in a 
high quantum yield chemiluminescent reaction, according to the following 
equation: 
 
D-luciferin + ATP + O2  Oxyluciferin + PPi + AMP + CO2 + light 
 
 
The amount of the emitted light corresponds directly to the ATP concentration. 
100 µL substrate solution (containing lysis solution and luciferin/luciferase) were 
added to each well containing the cells in 100 µL PBS. The microplate was 
incubated for 10 min in the dark. The luminescence was measured by means of a 
Mg2+ 
Luciferase 
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VICTORTM Multilabel Counter (Perkin Elmer, Waltham, USA) equipped with  
96-well (white) plates. The unknown ATP concentrations can be calculated on the 
basis of the ATP-standard curve. 
3.10 Lactate measurements 
HaCaT cells have been incubated 6 h with melatonin 1 nM in PBS (containing 8 
g/L NaCl, 0.2 g/L KCl, 1.11 g/L Na2HPO4, 0.2 g/L KH2PO4), after the first 2 h, 
incubation cells. CHO and 7PA2 cells were grown in 6-well plates to 80–90% 
confluence. In order to energetically synchronize the cells, cells were starved 1 h 
from glucose in PBS containing Ca2+ 0.9 mM and Mg2+ 0.5 mM. Thereafter, 
glucose, 1 mM, was re-added to the cells for a further 3 h, in the presence or 
absence of myxothiazol and antimycin A (10 µM each in HaCaT cells; 5 µM each 
in CHO and 7PA2 cells), two inhibitors of the mitochondrial respiratory chain 
[408]. After incubation the cells still adherent on the flask were acidified with 80 
mM HClO4 and the cell supernatants were centrifuged at 4 °C, 1000 x g for 10 
min; the lactate-containing supernatant was assayed (after preservation at 80 °C) 
spectrophotometrically (UV-visible Jasco-V550) by the method of Everse [409] 
following at 363 nm the production of 3-acetylpyridine-NADH catalyzed by 
bovine heart lactate dehydrogenase: 
 
 
Lactate + 3-acetylpyridine-NAD+    →  Pyruvate + 3-acetylpyridine-NADH + H+ 
 
The spectrophotometer was set at 363 nm on a kinetic program. 800 µl of Na-
borate buffer (Na2B4O7 · 10 H2O; 0.01 M; pH 9.2), 100 µl of 3-acetylpyridine-
NAD+  (20 mg/ml solution) and 100 µl of the sample or standard or blank (PBS 
plus 1 mM glucose) were added into the cuvette (Vcuvette = 1 ml). The absorbance 
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of the reaction mixture was followed for 2 minutes to stabilize the measure. After 
the addition of 10 µl of lactic dehydrogenase (LDH) enzyme (5 mg/ml), the 
absorbance of the reaction mixture was followed for 20 minutes to measure the 
lactate concentration.  
3.11 Reactive Oxygen Species, measurements 
Cell ROS generation was assessed by using the fluorescent probe 2´,7´-
dichlorodihydrofluorescein diacetate (DCFDA). Before the experiment, HaCaT 
cells, incubated 6 h in the presence and absence of 100 µM and 1 nM melatonin 
were trypsinized, pelleted at 1000 × g for 5 min at 20 °C, and resuspended in 
Hank’s buffer at the density 1×106 cells/ml. The CHO and 7PA2 cells were 
treated under the same conditions. Cell suspensions (1×106 cells/ml) were plated 
in 24-well (black) plates. When necessary 500 µΜ H2O2 was added. The relative 
fluorescence emission, after cell loading of DCFDA 100 µM, was followed of 520 
nm (VICTORTM Multilabel Counter, Perkin Elmer).  
3.12 Statistics 
The number of independent measurements is indicated in figure legends. 
Significance was determined using the Student t-test, run by Excel (Microsoft 
Windows platform). The error bars correspond to the standard error of the mean 
(SEM); all P values correspond to two-sided sample t-test assuming unequal 
variances. A P value ≤ 0.05 was considered significant. 
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4. RESULTS 
4.1 Melatonin determination in HaCaT cells. 
The effect of melatonin in HaCaT cells was explored after incubation of 
melatonin to the cell culture media for a variable time and at different 
concentration. Although melatonin is known to interact with cell surface specific 
receptors, the direct entry of melatonin into the cell can also occur; for these 
reasons first of all the presence and stability of melatonin was investigated in 
HaCaT cells by immunoassay using the ‘‘Direct saliva Melatonin ELISA kit’’. 
HaCaT cells were incubated with 1 nM melatonin for 1 h and 5 h, and the amount 
of melatonin up-taken by the cells was measured after cell lysis. 
 
Cell melatonin concentration 
pmoles / 1 x 10
6
 cells (± SEM)  
Control  1,50 x 10
3
 ± 0,0003  
Melatonin (1 h incubation)  65,46 x 103 ± 0,011*  
Melatonin (5 h incubation)  52,86 x 103 ± 0,0063*  
 
* P ≤ 0.05 
 
 
Table 1: Cell melatonin concentration. HaCaT cells were incubated with 1 nM melatonin for 1 h 
and 5 h. After incubation, the cells (1 x 106 / mL) were lysed for ELISA immunoassay and 
melatonin concentration was evaluated.   
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The results are reported in Table 1 and show that under the conditions chosen a 
significant amount of melatonin enters into the cells, without significant changes 
whether the incubation time is 1 h or more. The concentration of intracellular 
melatonin measured is, in fact, comparable after 1 h or 5 h incubation, on the 
other hand this value is ~ 60 times higher than that of control cells. 
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4.2 Effect of melatonin on NOS(s) mRNA expression in HaCaT cells. 
To investigate about the possibility that melatonin could influence cellular 
pathways involving NO metabolism, the production of mRNA for the different 
NOS isoforms was tested after incubation of melatonin in HaCaT cells. At first 
HaCaT cells were incubated for 6 h with increasing amounts of melatonin, from 
0.5 nM to 1 µM. 
 
 
 
Fig. 20: Dependence of NOS expression with melatonin concentration. HaCaT cells were 
incubated 6 h with increasing amounts of melatonin, as indicated. QRT-PCR analysis were carried 
out in the presence of primers for eNOS (violet) and nNOS (cyan). Relative expression was 
calculated versus Control, after β-actin normalization. iNOS was assayed but not detected (not 
shown). Data ± SEM; n = 9. **P ≤ 0.01 versus Control (modified from Arese et al., 2012).  
 
Chapter 4.  Results  
 
8 6  
 
As shown in Fig. 20, compared with controls, 0.5 and 1 nM melatonin produced a 
2.15- and 4-fold increase, respectively, of the nNOS mRNA level, whereas at 
melatonin concentration higher than 1 nM, the nNOS mRNA expression back 
decreased to the level of control cells. The eNOS mRNA expression level was 
insensitive to melatonin under all conditions and regardless to time of incubation. 
The iNOS mRNA, also, remained undetectable under the same conditions (not 
shown).  
The time dependent profile of the nNOS expression observed upon 7.5 h, 1 nM 
melatonin incubation, is shown in Fig. 21. 
 
 
 
Fig. 21: Time-dependence of nNOS mRNA expression driven by 1 nM melatonin. HaCaT cells 
were incubated with melatonin 1 nM, as a function of time, as indicated. QRT-PCR analysis were 
carried out in the presence of primers for nNOS. Relative expression was calculated versus 
Control, after β-actin normalization. Data ± SEM; n = 12. ** P ≤ 0.01 versus Control; * P ≤ 0.05 
versus Control (modified from Arese et al., 2012). 
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The nNOS mRNA expression level increases with the incubation time, reaching a 
maximum at 6 h. 
4.3 nNOS protein expression in HaCaT cells driven by melatonin.  
To evaluate that melatonin induces an increase not only of the mRNA but also of 
the protein, the protein nNOS expression level was investigated by Western Blot 
analysis in HaCaT cells incubated for different time with 1 nM melatonin.  
 
 
 
Fig. 22: Time-dependent expression of nNOS protein by melatonin. HaCaT cells were incubated 
with 1 nM melatonin, as a function of time, as indicated and then assayed for Western Blot with 
anti-nNOS antibodies. Data represent the densitometric value of each condition shown as fold 
increase versus the nNOS protein expressed by Control cells. Data ± SEM, n ≥ 3. ** P ≤ 0.01 
versus Control. Inset: Image of a typical Western Blot experiment carried out with antibody 
against nNOS after 8 h incubation in the presence and absence of 1 nM melatonin; α-tubulin as 
reference (modified from Sarti et al., 2013).  
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The nNOS protein expression changes as a function of time (Fig. 22). Compared 
to control, melatonin 1 nM induces a ~ 2 fold increase in nNOS expression after 8 
h of incubation. The nNOS synthesis reach a maximum after ~ 8 h incubation with 
1 nM melatonin, i.e., ~ 2 h after cell rising of the nNOS mRNA; timing of these 
processes is consistent with protein synthesis and maturation (Fig. 23).  
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Fig. 23: Time-dependent profile of the mRNA (blue) and protein (red) nNOS expression (modified 
from Sarti et al., 2013). 
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4.4 Nitrate/Nitrite (NOX) accumulation in HaCaT cells induced by melatonin.  
The production of NO was assessed by measuring nitrite and nitrate levels in the 
medium of HaCaT cells after 6 and 8 h incubation with increasing amounts of 
melatonin. The result of these experiments shows that the production of NOX by 
HaCaT cells is increased by melatonin compared to control (Fig. 24).  
The maximal effect on NOX accumulation is observed at about 1 nM melatonin 
tending to the basal level with increasing melatonin concentration by one or even 
two orders of magnitude. 
 
 
 
Fig. 24: Concentration dependence of NOX production by melatonin (nanomolar). HaCaT cells 
were treated with increasing melatonin concentrations (1, 10, 100 nM). NOX accumulation in the 
cell supernatant was quantified after 6 h (light bars) and 8 h (heavy bars) incubation with 
melatonin. Data ± SEM; n ≥ 5. ** P ≤ 0.01 versus Control (modified from Sarti et al., 2013). 
 
The time dependence effect of melatonin 1 nM on NOX accumulation are shown 
in Fig. 25. The production of nitrite and nitrate in the supernatant of the cells 
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treated with 1 nM melatonin increases with the time of incubation respect to 
control untreated cells and reach a peak at 8 h. Under these condition the NOX 
accumulation is 2 times higher than the NOX accumulated for a corresponding 
time (8 h) in controls. 
 
 
 
 
 
Fig. 25: Time-dependence NOX production of nM melatonin. NOX accumulation was measured 
in the cell supernatant of HaCaT cells incubated with 1 nM melatonin as a function of time. a) 
Data shown as nmoles NOX / 1x106 cells b) Data shown as fold increase versus Control 
(corresponding to untreated cells incubated for the same time as treated cells). Data ± SEM, n ≥ 5. 
** P ≤ 0.01 versus Control (modified from Sarti et al., 2013). 
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4.5 Melatonin on mitochondrial membrane potential in HaCaT cells. 
The mitochondrial membrane potential of HaCaT cells was measured following 
the import of the fluorescent probe JC-1 into mitochondria and the consequent 
formation of the red J-aggregates occurring when the ∆Ψ is ≥ 200 mV.  
In a typical experiment, cells were pre-mixed with 300 nM JC-1 in the presence of 
2 µM ouabain that prevents the hyperpolarization of the plasma membrane The 
reaction was started by the addition of nigericin (600 nM), a ionophore which 
converts ∆µH+ into ∆Ψ.  
The kinetics of JC-1 import and the formation of the aggregates where than 
followed, observed as the increasing level of red fluorescence and analysed. A 
plateau level is reached in about 60 min. Afterwards 200 nM valinomycin was 
added to the mixture, causing dissipation of the mitochondrial ∆Ψ and bringing 
back the fluorescence red signal to a basal level. The differences between the 
maximum fluorescence level at plateau and the minimum obtained upon addition 
of valinomycin, the ∆F, is proportional to ∆µH+. As shown in Fig. 26, after 6 h 
incubation with 1 nM melatonin the mitochondrial membrane potential (∆µH+) is 
lowered, by ~ 20 %, compared to control, whereas increasing concentration of 
melatonin didn’t affect the mitochondrial membrane potential. 
Moreover, the level of fluorescence is maximal when the NOS substrate arginine 
is removed from the cell culture medium, pointing to a correlation between the 
level of ∆Ψ and the activity of NOS. Interestingly, the mitochondrial ∆Ψ-
depression induced by melatonin was reverted by washing cells and allowing 
further 3 h incubation in a melatonin-free medium. 
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Fig. 26: Melatonin on mitochondrial membrane potential. a) Time-dependent accumulation of JC-
1 in mitochondria, started by the addition to the cells of nigericin 0.6 µM (Nig). Valinomycin (Val) 
is added (at plateau) to collapse the membrane potential. Excitation wavelength = 490 nm, 
emission wavelength = 590 nm. Cells maintained in the absence of the NOS substrate arginine 
(red); Control cells (black). Cells after 8 h incubation with 1 nM melatonin (cyan). b) ∆Fmax, 
calculated from plateau to the fluorescence level reached on addition of valinomycin. Data ± SEM; 
n = 4. * P ≤ 0.05 versus Control; # P ≤ 0.05 versus no Arg; # # P ≤ 0.001 versus no Arg. c) ∆F 
decrement (∆∆F %) of melatonin treated cells (cyan) versus Control at 6 or 9 h (gray). After 
melatonin incubation, cells were washed and incubated further 3 h (i) without melatonin (blue) and 
(ii) with melatonin renovated in the medium (cyan). Data ± SEM; n = 4 (modified from Arese et. 
al., 2012). 
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4.6 Evaluation of respiration efficiency of HaCaT cells treated with 
melatonin. 
The effect of melatonin on the modulation of bioenergetic of HaCaT cells was 
evaluated following the spontaneous rate of oxygen consumption carried out by 
intact cell mitochondria.  
 
 
 
 
Fig. 27: Oxygen consumption rate in HaCaT cells: effect of melatonin on cell respiration. a) 
Comparative respiration rate of HaCaT cells incubated in the absence or in the presence of nM 
melatonin. Respiration was measured and reported as percent of the O2 consumption of Control. 
Data ± SEM, n ≥ 3. ** P ≤ 0.01 versus Control. b) Typical O2 consumption profiles of melatonin-
treated HaCaT cells, in the presence (red) and absence (cyan) of the nNOS inhibitor 7-
nitroindazole (7N); control untreated cells (black). Inset: 1st  derivative plot of the traces (modified 
from Sarti et al., 2013). 
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After incubation for 8 h with increasing amounts of melatonin, HaCaT cells were 
resuspended in Hank’s 1 g/L glucose at a cell density of 3.3 × 106 cells / ml and 
cell respiration driven by endogenous substrates was measured.  
As shown in Fig. 27a, when cells are treated with 0.5-1 nM melatonin, a ~ 10 % 
loss of cell respiration is observed; the effect decreases at higher melatonin 
concentrations (up to two orders of magnitude). 
Fig. 27b show typical oxygen consumption profiles of HaCaT cells treated with 
melatonin, in the presence (red) and the absence (cyan) of the specific nNOS 
inhibitor, 7-nitroindazole (7N). 
The results indicate that the oxygen consumption of cells incubated 8 h with 
melatonin is lower than that of control cells (black line) and that the addition of 
500 nM 7N 30 minutes before the measurement reverts the inhibition of 
respiration induced by melatonin. 
To further insight the molecular mechanism responsible of this inhibition, the 
involvement of the mitochondrial respiratory chain complexes was evaluated after 
cell permeabilazation with digitonin, and making use of a mitochondrial complex 
specific substrate/inhibitor titration approach [406]. For this purpose, HaCaT 
cells, pre-treated 8 h in the presence and absence of 1 nM melatonin, were 
resuspended in the respiration medium (as described in Materials and Methods) at 
a cell density of 3.3 x 106 cells / ml. Initially the basal respiration, measured in the 
absence of digitonin and exogenous reducing substrates, was evaluated. Figure 
28a represents a typical respiration trace of control HaCaT cells. When the signal 
becomes stable, digitonin is added to the cells in order to induce a loss of 
plasmatic membrane integrity and to allow the consequent access of substrates 
into the cells. 
Chapter 4.  Results  
 
9 5  
 
 
 
Fig. 28: Effect of melatonin on respiratory complexes activity in digitonin-permeabilized HaCaT 
cells. a) Oxygen consumption rate of 5×106 control cells. Dig: digitonine (8 µg/ml); Pyr/Mal: 
pyruvate (8.8 mM) and malate (4.4 mM); ADP: adenosinetriphosphate (4 mM); Rot: rotenone (0.5 
µM); Suc: succinate (10 mM); Ant a: antimycin A; ASC/TMPD: ascorbate (2mM) and TMPD (0.5 
mM); Cyt c: cytochrome c (10 mM). b) Respiration rate values in HaCaT cells treated 8 h in the 
presence and absence of 1 nM melatonin recorded after each addition step (of substrate/inhibitor) 
during the trace. Data values are the means ± SEM; n ≥ 4. * P  ≤ 0.05 versus Control. 
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Figure 28b reports the respiration rate values of cells treated and untreated with 
melatonin after each addition. As shown in this figure the basal respiration is 
lower in HaCaT cells incubated with melatonin respect to control cells. As shown 
in figure 28a, within 10 minutes incubation with 8 µg/ml digitonin, cell respiration 
slowly decreases to approximately 50 % of the  initial value, as expected due to 
partial membrane permeabilization and loss of reducing substrates and ADP. The 
addition of 2 mM ADP, 8.8 mM pyruvate and 4.4 mM malate induces an increase 
in cell respiration. 
In the presence of digitonin, infact, pyruvate, malate and ADP can enter into the 
cells. Pyruvate and malate are substrates generating NADH, therefore at these 
stage, the respiration driven by Complex I was observed and interestingly is about 
20 % lower in HaCaT cells incubated with 1 nM melatonin than in control cells 
(Fig. 28b). The addition of 0.5 µM rotenone (Rot), inhibitor of Complex I, 
abolishes almost completely respiration. After the addition of 10 mM succinate, 
the substrate that reacts directly with Complex II, the oxygen consumption was 
restored. Under these conditions the differences of respiration rate between 
HaCaT cells incubated in the presence and absence of melatonin are maintained, 
although attenuated. 5 µM Antimycin A (Ant a), by inhibiting Complex III, 
almost abolishes respiration, restored by adding reduced cytocrome c in the 
presence of ascorbate (ASC) and TMPD. Ascorbate maintains TMPD in a reduced 
state so that electrons can flow freely from TMPD to cytochrome c. These 
conditions ensure the highest electron transfer efficiency at the complex IV site. 
The O2 consumption rate  reached respectively 336 pmol O2 s-1 mg-1 of  proteins 
for control cells and 260 pmol O2 s-1 mg-1 of proteins for cells incubated with 1 
nM melatonin. The addition of exogenous cytochrome c to the respiring cells did 
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not affect respiration, proving the integrity of the mitochondrial outer membrane, 
and suggesting that, as performed, the mild digitonin treatment causes small ions 
and molecules permeabilization, but not loss of cytochrome c, at least on the time 
window explored (Fig. 28b).  
4.7 Determination of variation in ATP levels in melatonin treated cells. 
The effects of melatonin on the cellular metabolism were explored by measuring 
the ATP and lactate production. The ATP concentration levels of cells treated for 
6 h with melatonin, 1 nM, was assayed either at steady state in the presence or 
absence of glucose or kinetically by following the rate of ATP production (Fig. 
29). The stationary ATP concentration of the cells was performed  in the presence 
or absence of 11 mM glucose for 4 h and 2.5 µg/ml oligomycin during the last 1.5 
h of incubation. The starvation of glucose is necessary to minimise glycolysys and 
the ATP-synthase inhibitor oligomycin to inhibit OXPHOS. As shown in figure 
29a in the presence of glucose the ATP concentration of cells treated or not with 
melatonin and/or olygomycin is similar as expected based on the contribution of 
both glycolysis and OXPHOS to ATP formation. After cell glucose starvation and 
upon minimizing the glycolitic contribution, the ATP level decreases and the 
addition of oligomycin induces a significant inhibition of ATP production (Fig. 
29b). Under these conditions, the difference  between the ATP measured in the 
absence and presence of olygomicyn (∆ATP) is indicative of ATPOXPHOS. The 
ATPOXPHOS value divided by the basal ATP concentration, measured in the 
presence of glucose, approximates the fraction of ATPOXPHOS/ATPtotal. This 
fraction (Fig. 29c) is lower in melatonin treated cells compared to controls. 
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Fig. 29: Effect of melatonin on the ATP production. (a, b, c) Stationary ATP concentration levels 
evaluated in intact HaCaT cells (5 x 105/ml) in the presence and absence of melatonin 1 nM, 
oligomycin 2.5 µg/ml and glucose 11 mM, as specified in the figure. Omy: oligomycin. a) 
Measurements of ATP in the presence of glucose. b) Measurement of ATP in the absence of 
glucose. ∆ATP = ATPOXPHOS. c) Fractional ATP (f) = ATPOXPHOS / ATPtotal; ATPOXPHOS = ∆ATP 
(panel b); ATPtotal has been measured in the presence of glucose and absence of oligomycin. Data 
± SEM; n = 12. ** P ≤  0.01 versus Control. d) Rate of mitochondrial ATP synthesis. Data ± SEM, 
n ≥ 14. ** P ≤ 0.01 versus Control (modified from Arese et al., 2013). 
 
Chapter 4.  Results  
 
9 9  
 
The effect of melatonin on the ATPOXPHOS production was assessed directly by 
measuring the rate of succinate-driven ATP synthesis [407]. As shown in figure 
29d, the rate of ATP production (nmoles ATP/minutes/1x106 cells) is lower in 
cells treated with melatonin than in untreated cells. After 6 h incubation with 1 
nM melatonin the rate of ATP production is 0.51 (± 0.044) nmoles/min/106 cells 
to be compared with 0.69 (± 0.028) nmoles/min/106 cells of control cells. This 
result suggest that melatonin induces approximately 30% depression of 
ATPOXPHOS production. 
4.8 Effect of melatonin on lactate production in HaCaT cells. 
The effect of 1nM melatonin on the relative contribution of OXPHOS  and 
glycolysis to the overall ATP production was independently evaluated by 
comparing the concentration of lactate produced by HaCaT cells incubated for 3 h 
at 37 °C in a medium containing 1 mM glucose and in the absence or presence of 
the respiratory chain inhibitors, antymicin A and mixhotiazole both at 10 µM 
concentration. Cells were pre-incubated for 1 h in a glucose free medium to 
prevent differences in the availability of endogenous substrate. As shown in figure 
30a, the basal lactate concentration in controls is on average 68 µg / 1 x 106 cells; 
this value rises to 80 µg/ 1 x 106 cells after melatonin treatment.  
The melatonin induced increase of lactate production is consistent with the 
conclusion that melatonin partially inhibits OXPHOS, and glycolysis is 
compensating. As expected, in the presence of antimycin A and myxothiazole, the 
lactate increases in controls as in melatonin treated cells; in these latter, however, 
to a minor extent as if stimulation of glycolysis was additive. Assuming that the 
Warburg effect compensates exactly for the inhibition of respiration induced with 
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inhibitors, it follows that the amount of lactate, produced under basal conditions is 
equivalent to the glycolytic ATP, whereas the difference between the lactate 
produced in the presence of the inhibitors and the basal glycolitic lactate, defined 
as ∆lactate, is proportional to ATPOXPHOS. 
 
 
 
Fig. 30: Effect of melatonin on the lactate accumulation in the medium of HaCaT cells. a) Lactate 
production assayed in HaCaT cells incubated 6 h with 1 nM melatonin and 3 h with 1 mM glucose 
and in the presence and absence of myxothiazol (Myxo) and antimycin A (Ant A), 10 µM each. 
Basal lactate is produced by the cells in the absence of inhibitors and has been taken as ≈ 
ATPglycolytic. The lactate produced in the presence of inhibitors has been taken as the maximal 
lactate (total). The difference between lactate produced in the presence of inhibitors and basal 
lactate is indicated as ∆lct; ∆lct ≈ ATPOXPHOS. b) Ratio between basal lactate and ∆lct, as indicative 
of the ATPglycolytic/ATPOXPHOS ratio. Values are the means ± SEM; n = 4. * p ≤ 0.05 versus Control 
(modified from Arese et al., 2013). 
 
The basal lactate divided by ∆lactate has been taken as indicative of the ratio 
between ATP glycolitic and OXPHOS. As shown in figure 30b, the 
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ATPglycolytic/ATPOXPHOS ratio is lower in control (~ 1.1) than in cells treated with 
melatonin  (~ 2.1).  
4.9 Effect of melatonin on ROS production in HaCaT cells. 
The evaluation of ROS production, carried out using HaCaT cells pre-loaded with 
the DCFDA fluorescent probe, showed that the ROS accumulation is lower in 
HaCaT cells incubated 6 h with melatonin 100 µM than in control cells, by ~ 
20%, whereas the ROS production in HaCaT cells  treated 6 h with melatonin 1 
nM is comparable with Control cells (Fig. 31). 
 
 
 
Fig. 31: Effect of melatonin on reactive oxygen species (ROS) production. ROS production was 
measured in cell suspension (at density 106/ml) containing DCFDA 0.1 mM. H2O2 500 µM was 
added, as indicated. The kinetics of DCFDA fluorescence was followed for 120 min. The 
percentage of ROS production is taken at 100 min. Data values are the means ± SEM; n ≥ 8. **P ≤ 
0.001 versus Control. 
 
 
Chapter 4.  Results  
 
1 0 2  
 
Consistent with literature, the addition of 500 µΜ H2O2 induced an enhancement 
of ROS production, less evident, however, in HaCaT cells incubated with 100 µM 
melatonin. Under these conditions, the effect shown in the results previously 
reported can not be attributed to the antioxidant activity of melatonin but rather to 
a specific cell signalling occurring at low nM concentration.  
4.10 Citrate Synthase 
The citrate synthase activity of HaCaT cell treated 8 h with melatonin was 
evaluated.  
 
 
 
Fig. 32: Citrate Syntase in HaCaT cells. HaCaT cells, incubated in the presence and absence of 1 
nM melatonin were lysed. Cell lysates were assayed for Citrate Synthase spectrophotometrically. 
Data values are the means ± SEM; n ≥ 3.  
 
As shown in Fig. 32, HaCaT cells (1x106) used as such or after incubation with 
melatonin display a similar citrate synthase activity. 
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4.11 Nitrate/Nitrite (NOX) accumulation in CHO and 7PA2 cells 
The amount of NO produced by CHO and 7PA2 cells was evaluated measuring 
the nitrate and nitrite (NOX) content in the cell medium after 4 h of accumulation 
(see Methods).  
 
 
 
Fig. 33: NOX production in CHO e 7PA2 cells. NOX content in the supernatant of CHO and 7PA2 
cells measured after 4 h of accumulation. Data shown as fold increase versus control (CHO). Data 
+/− SEM, n ≥ 7. ** P ≤ 0.01 versus CHO. 
 
The result is reported in figure 33 and show that the NOX produced by 7PA2 cells 
is significantly higher than that of control (CHO) cells. Compared to control, 
7PA2 cells are characterized by a  ~ 2.5 fold increase in NOX accumulation. 
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4.12 ROS production in CHO and 7PA2 cells 
The intracellular ROS generation was measured fluorimetrically in CHO and 
7PA2 cells (see Methods). The results show that the 7PA2 cells ROS level is 
higher compared to the CHO controls. ROS production by 7PA2 cells is ~ 25 % 
higher than in controls (see Fig. 34). 
 
 
Fig. 34: ROS production in CHO e 7PA2 cells. ROS production in CHO and 7PA2 cells measured 
following the kinetics of DCFDA fluorescence for 120 min. The percentage of ROS production is 
taken at 60 min. Data values are the means ± SEM; n = 8. ** P  ≤ 0.001 versus Control (CHO) 
(modified from Krako et al., 2013). 
4.13 Mitochondrial membrane potential in CHO and 7PA2 cells 
The mitochondrial membrane potential of CHO and 7PA2 cells was assayed 
following the accumulation into the mitochondrial matrix of the fluorescent 
cationic probe JC-1 and the  accumulation of red fluorescent J-aggregates into the 
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mitochondrial matrix, in the presence of  nigericin, converting ∆pH in ∆ψ. 
Typical kinetics of red fluorescence accumulation in 7PA2 cells and CHO 
controls are shown in figure 35a. The differences between the maximum, reached 
about 60 minutes after addition of nigericin, and the minimum obtained upon 
addition of 0.2 µM valinomycin is defined as ∆F and is proportional to ∆µH+. 
Valinomycin causes mitochondrial dissipation of the ∆Ψ  leading to a fast 
bleaching of the fluorescence signal. 
 
 
 
Fig. 35: Mitochondrial membrane potential in CHO and 7PA2 cells. a) Time-dependent JC-1 
accumulation into mitochondria of CHO and 7PA2 cells (3x106 cells/ml). The differences between 
the maximal fluorescence, reached about 60 minutes after addition of 0.6 µM nigericin (NIG), and 
the minimum obtained upon addition of 0.2 µM valinomycin (VAL) is the ∆F proportional to 
∆µH+. b) ∆F values, the level of mitochondrial membrane potential of CHO and 7PA2 cells 
normalized for 1x106 cells/ml was reported as the ∆F obtained as in panel a. Data ± SEM, n  ≥ 13. 
** P ≤ 0.001 versus Control (CHO) (modified from Krako et al, 2013). 
 
As shown in figure 35b, the 7PA2 cells are characterized by an approximately 
60% lower mitochondrial membrane potential compared to CHO controls. 
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4.14 Mitochondrial respiration in CHO and 7PA2 cells 
Cell O2 consumption has been evaluated oxygraphically in intact CHO and 7PA2 
cells respiring under basal metabolic conditions. Nigericin was added to allow 
maximal ∆ψ formation and once reached valynomicin was added. In the presence 
of both ionophores the H+ electrochemical potential gradient is fully collapsed and 
the control (inhibition) exerted on the respiratory chain is abolished. The 7PA2 
cells display an approximately 30% decrease of basal respiration, compared to 
controls (Fig. 36a). In the presence of both ionophores cell respiration increases 
by a factor of ∼ 2.4 in control CHO cells and 1.6 in 7PA2 cells (see Fig. 36b).  
 
 
 
Fig. 36: Cell respiration and respiratory control ratio of CHO and 7PA2 cells. a) Oxygen 
consumption of intact cells (3,3×106 cells/ml). Basal: respiration rate overall; NIG: respiration rate 
after addition of 0.6 µM nigericin; NIG/VAL: respiration rate measured after the subsequent 
addition of 0.2 µM valinomycin to cells respiring in the presence of nigericin. b) Respiratory 
control ratio (RCR) obtained as the ratio between the rate observed in the presence of both 
nigericin and valinomycin (NIG/VAL) and in their absence (Basal respiration). Data values are the 
means ± SEM; n  ≥ 5. ** P ≤ 0.001 versus Control (CHO) (modified from Krako et al., 2013). 
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The contribution of the respiratory complexes to cellular respiration was evaluated 
in CHO and 7PA2 permeabilazed cells following the protocol published by 
Kuznetsov and collaborators, as adapted to our cell lines.  
 
 
 
 
Fig. 37: Cellular respiration in digitonin-permeabilized CHO and 7PA2 cells. a) Typical oxygraph 
trace of 5×106 CHO cells. Blue line: oxygen concentration trace; red line: O2 flux, i.e., oxygen 
consumption rate. b) Respiration rate values in CHO and 7PA2 cells recorded after each addition 
step (of substrate/inhibitor) during the trace. Data values are the means ± SEM; n ≥ 5. * P ≤ 0.05 
versus Control (CHO); ** P ≤ 0.001 versus Control (CHO) (modified from Krako et al., 2013) . 
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Briefly, as shown in figure 37a, when the oxygraphic signal becomes stable, 
digitonin is added to the respiring cells. The digitonin concentration used and its 
incubation time was optimized to the sensitivity of the cells, by mean of a 
concentration and time dependence titration; optimal substrate permeation was 
obtained using 1.8µg digitonin /1x106 cells, for 10min. After the addition of 
digitonin, the oxygen consumption slowly decreases and reaches a minimum 
value within 10 minutes of incubation. The addition of NADH generating 
substrates (pyruvate and malate), followed by addition of ADP fully restores 
respiration. As shown in figure 37b, at this step, the oxygen consumption of 7PA2 
cells is significantly lower by ~ 40 % than controls. The addition of rotenone leads 
to the inhibition of Complex I and consequently respiration is arrested. The 
addition of succinate stimulates Complex II activity and allows respiration to 
restart bypassing Complex I. Under these conditions, the difference of respiration 
between 7PA2 and control cells though maintained, looks somewhat attenuated, 
as if impairment of Complex I in 7PA2 cells was higher than that of Complex II. 
To assess the Complex IV activity, the respiration was inhibited Antimycine A, a 
specific  inhibitor of Complex III, in the presence of exogenous reductants of 
complex IV via cyt c, namely Ascorbate and TMPD. The respiration of 7PA2 
cells at this step is more than 20 % lower respect to CHO control cells (Fig. 37b). 
In the last step, reduced cytochrome c is added to respiring cells; the absence of 
effects on the rate of respiration proves the integrity of mitochondrial outer 
membrane. In conclusion, the 7PA2 cells show an impairment of electron transfer, 
more evident at the level of complex I and complex IV. 
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4.15 ATP production by CHO and 7PA2 cells 
The CHO and 7PA2 ATP concentration level was measured in the presence or 
absence of 1 mM glucose. Glucose starvation was performed to promote 
OXPHOS while minimizing the glycolitic contribution to the ATP production. In 
the absence of glucose the addition of 2.5 µg/ml oligomycin induces a dramatic 
decrease of ATP, due to OXPHOS inhibition. Under these condition, the 
difference between the ATP measured in the absence and presence of oligomycin, 
defined in figure 38a as ∆ATP is, within a gross approximation, indicative of the 
ATPOXPHOS (fig. 38a).  
 
 
 
Fig. 38: ATP production in CHO and 7PA2 cells. ATP measurements evaluated in intact CHO and 
7PA2 cells (5×105/ml) in the presence and absence of oligomycin 2.5 µg/ml and glucose 1mM. a) 
Measurement of ATP after 3 h cell glucose starvation. ∆ATP: difference of ATP measured in the 
absence and in the presence of oligomycin (corresponding to ATPOXPHOS). b) Measurements of 
ATP in the presence of 1mM glucose. Omy = oligomycin. Data ± SEM; n ≥ 6 (modified from 
Krako et al., 2013).  
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The results suggest that the ATPOXPHOS levels  is more than 20 % lower in 7PA2 
cells compared to CHO cells. In the presence of glucose
 
the ATP concentration 
increases and the effect of oligomycin is no longer evident, this is due to 
glycolysis compensation to OXPHOS inhibition (Warburg effect). 
As shown in figure 38b under this condition a fully efficient glycolytic induction 
response is operative in CHO cells where the ATP concentration is the same 
before and after treatment with oligomycine. This is not the case of 7PA2 cells, 
displaying a ∼ 20 % decrease of the total ATP concentration (OXPHOS + 
glycolytic), that becomes even more evident when OXPHOS is inhibited by 
oligomycin. 
4.16 Lactate production in CHO and 7PA2 cells 
The lactate production by CHO and 7PA2 cells was evaluated before and after 
treatment of Complex III inhibitors (antymicin A and mixhotiazole). The lactate 
produced under basal conditions is higher in 7PA2 cells than in control CHO 
cells. This result is fully consistent with a different glycolytic contribution to ATP 
synthesis in the 7PA2 and control cell lines. As expected, in the presence of 
OXPHOS inhibitors, some additional lactate is produced, due to glycolytic 
compensation of ATP loss (Warburg effect). These results are reported in figure 
39, where the histogram bar is divided in two parts, for each cell lines: the lower 
part (light grey) represent the basal lactate production, while the higher part 
(violet) represent the compensating Warburg lactate. This Warburg lactate is 
indicative of the OXPHOS contribution to ATP synthesis. The basal lactate 
production of 7PA2 cells is ~ 47 % of the total lactate, to be compared to ~ 38 % 
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of the CHO control cells, whereas the Warburg lactate production is ~ 53 % in 
7PA2 cells and 62 % in controls. 
 
 
 
Fig. 39: Lactate production in CHO and 7PA2 cells. Lactate accumulation in the cell medium of 
CHO and 7PA2 cells after 2.5 h of incubation in the presence of glucose 1 mM and in the presence 
and absence of myxothiazol and antimycin A, 5 µM each. The lactate produced in the presence of 
inhibitors has been taken as the maximal lactate (total, 100 %). The difference between total and 
basal lactate is the Warburg lactate (violet); Warburg lactate ≈ ATPOXPHOS. The lactate produced in 
the absence of the inhibitors is the Basal lactate (grey); Basal lactate ≈ ATPglycolytic. Values are the 
means ± SEM; n ≥ 5 (modified from Krako et al., 2013). 
 
 
This data strengthen the hypothesis that in 7PA2 cells OXPHOS is impaired and 
glycolysis compensates. 
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5. DISCUSSION AND CONCLUSION 
 
The nitrogen monoxide (NO), nitric oxide in the literature, is a biological 
messenger which regulates several and important physiological responses 
including relaxation of smooth muscle, neurotransmission, cell migration and 
mitochondrial respiration [40, 41, 43-45]. NO is implicated not only in numerous 
physiological processes but also in several pathologies such as hypertension, 
cardiovascular dysfunctions, neurodegeneration, arthritis, asthma and septic shock 
[68-85]. Evidence is growing that the (physiological versus toxic) effects of NO 
resides on its concentration levels: NO in the low concentration range (pico-
nanomolar) induces physiological responses, whereas NO in the high 
concentration range (micromolar) is involved in several pathologies. The NO 
concentration level in the cell varies depending on the relative rate of its 
production, degradation and scavenging. A wide variety of biological responses 
has been observed influencing these processes and consequently lowering or 
enhancing the nitric oxide availability. The enzymatic endogenous NO production 
depends on the activation or inhibition of the nitric oxide synthase (NOS) whose 
activity is controlled by different stimuli or effectors. The NO concentration level 
is also influenced by the specific NOS isoforms activated: the constitutive NOSs, 
i.e. the endothelial NOS (eNOS) and the neuronal NOS (nNOS), producing NO in 
the nM range, whereas the inducible NOS (iNOS) releasing up to µM NO. In the 
cell, the NO availability is controlled by NO scavengers, such as hemeproteins or 
reduced glutathione. The NO recycled from nitrite is also relevant to its 
bioavailability.   
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It is nowadays established that NO inhibits mitochondrial respiration. The 
inhibition is induced by the reaction of NO with some of the respiratory chain 
complexes, particularly with Complex I and IV, according to mechanisms studied 
over about 25 years. The interaction between NO and complex IV, cytochrome c 
oxidase (CcOX), is of particular interest, being rapid and reversible [51-55]. The 
reaction of NO with mitochondrial complexes has a potential patho-physiological 
relevance for the implications on cell bioenergetics and is therefore subject 
intensively studied. The transient and reversible inhibition of mitochondrial 
respiration may induce a physiological, compensatory activation of glycolysis 
[410]. This original observation by Warburg in our days has been re-proposed by 
Almeida and collaborators [56], who compared the different energetic behaviour 
of astrocytes and neurons inhibited by NO. In this respect, it is worth considering 
that different cell lines may trigger a different glycolytic compensatory activity in 
response to the NO inhibition of OXPHOS [56]. The evidence collected suggests 
that, if NO remains available in the mitochondrial environment, the mitochondrial 
membrane potential decreases, and glycolytic contribution became relevant to 
ATP synthesis. Thus, it seems crucial that cells responding to NO pulses are 
endowed with an efficient glycolytic machinery able to compensate for the 
decreased aerobic ATP production [56, 411]. In the absence of a suitable 
glycolytic compensation, the ATP levels could decrease dramatically, leading to 
cell death [57].  
On this basis, we decided to explore the interplay between NO and cell 
bioenergetics both in a physiological context, such as HaCaT cells stimulated with 
physiological melatonin concentrations or in pathological frame such as cell 
model of Alzheimer’s disease. 
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Among its multiple physiological actions, it has been suggested that NO plays a 
key role also in the circadian and homeostatic regulatory processes of sleep [60-
63] [64-67]. NO, in fact, acts as a powerful sleep-promoting agent, as revealed 
following the production of nitrite and nitrate, characterized by a circadian night 
peak [412] and also considering that the nNOS activity is involved in the 
regulation of sleep-wake cycle [413, 414]. In vivo experiments using nNOS 
inhibitor or the nNOS KO mice strengthened the idea that REM sleep is regulated 
with nNOS-derived NO [67]. In the central nervous system (CNS), the nNOS 
mediates long-term regulation of synaptic transmission. In particular the nNOS 
seems to play an important role in long term potentiation (LTP) [415, 416]. LTP is 
a putative mechanism of memory formation in hippocampus [417]. Moreover, an 
impressive amount of evidence shows that inhibition of nNOS impairs learning 
and memory [90, 418-420]. Considering that sleep loss produces a decline in 
cognitive and motor performance [421], learning and memory deficits [422] and 
mood disturbances and that these effects are restored by prolongation and 
intensification of sleep [67], nNOS may be a joining link between the learning and 
memory processes and sleep.  
One of the principal agent in the regulation of sleep-wake cycle is melatonin, a 
small, lipophylic molecule, popular for preventing jetlag or as adjuvant in elderly 
people with sleep-problems [423]. Originally recognized as the hormone of the 
pineal gland, melatonin is produced also by other extrapineal sites [180]. In 
humans, the melatonin-generating system is photosensitive displaying a circadian 
rhythm, with the highest concentration levels produced at night, in the darkness 
[186]. Importantly, melatonin production decline with age [186, 354]. Among the 
wide diversity of physiological effect reported for melatonin [187, 189, 199, 201, 
203-216, 354], high relevant is the capacity to directly scavenge RONS [203, 204, 
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213]. The free radical-scavenging capacity of melatonin also extends to its 
metabolites in a free radical-scavenging cascade that prolongs its useful life [181]. 
Moreover, melatonin is able to induce the over-expression of antioxidant enzyme 
[271-275] and to inhibit pro-oxidant enzymes such as the iNOS [242, 276, 277].  
Stimulated by the notion that both melatonin and NO are involved in the 
regulation of sleep-wake cycle and that NO controls mitochondrial respiration, we 
decided to investigate whether a relationship between melatonin, nitric oxide and 
cell bioenergetics was operative.  
In contrast with what expected from the literature proposing melatonin as a simple 
chemical radical scavenger, using HaCaT cells in culture as targets, we have 
observed unexpectedly that nM melatonin induces the increase of the nNOS 
mRNA expression by a factor ~ 4. Consistently with a receptor mediated nuclear 
DNA-activated process, no effects of melatonin were observed at incubation times 
earlier than 3-4 h. According to our observations, the maximum peak of nNOS 
mRNA expression is observed after 6 hour of incubation with melatonin. At 
melatonin concentrations higher than nM, and/or by further extending the 
melatonin incubation time the nNOS expression decreases returning to a basal 
level; this kind of biphasic regulation suggests the existence of a time and 
concentration-dependent negative feed-back, finely, controlling of the nNOS 
mRNA expression by melatonin, at least in HaCaT cells. Moreover, within the 
limits of the heterogeneous distribution of melatonin among organ and tissues 
[263], it is intriguing that the concentrations of melatonin, in the nM range, 
inducing the observed changes of the nNOS mRNA are compatible with the 
melatonin circulating levels in the human blood at night (peak value ~ 100–200 
pg/mL, corresponding to ~ 1 nM melatonin) [180, 201]. The upregulation of the 
nNOS mRNA expression by melatonin appears specific, as indicated by the fact 
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that over the same time period, the eNOS expression remains constant and the 
iNOS is not detectable. The nNOS protein synthesis lags behind the rise of the 
corresponding nNOS mRNA: the protein increases transiently, and within hours, 
returns back to its basal level. The maximum peak of nNOS protein expression is 
observed after 8 h of incubation with melatonin. The ~ 2 h shift between the 
protein and the mRNA synthesis is consistent with a nuclear DNA-dependent 
pathway. Almost synchronously also the production of nitrate and nitrite (NOx) 
increases. An increase of NOX production in the culture medium of HaCaT cells 
was already observed after 6 h of incubation with melatonin and is even more 
increased after 8 h of incubation. This result shows that the last 2 hours of 
incubation are the most relevant time range where the nitrate and nitrite, and 
therefore NO, are produced. Interestingly, from the bioenergetic point of view, 
following incubation with nanomolar melatonin and on a time scale similar to that 
of both the nNOS changes and the NOx accumulation, the mitochondrial 
membrane potential decreases by ~ 20 %; the mitochondrial respiration also is 
slightly, but significantly depressed (~ 10 %) suggesting that under these 
conditions and at least in keratinocytes mitochondria, the mechanism(s) 
responsible for maintenance of ∆Ψ are more affected than respiration [424]. It is 
worth noting that when the cells were starved from the NOS substrate Arginine, 
the electrophoretic import of JC-1 was the highest, confirming that cultured cells 
express a basal NOS activity, releasing NO and depressing the mitochondrial 
potential to a measurable extent [31]. Furthermore the addiction of 7-nitroindazole 
(7N), specific nNOS inhibitor, to cells pre-incubated with melatonin reverts 
completely the decrease of cell respiration. These results indicate that in the 
presence of melatonin the inhibition of mitochondrial respiration is partial, 
reversible and mediated by NO. According to our measurements, the NO released 
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after a melatonin incubation limited in extent and time, would lead to a partial 
inhibition of Complex IV following predominantly the PW1 [8], leading to the 
formation of a labile Complex IV-NO2− derivative. Interestingly, and relevant to 
the melatonin effects herein described, the activity of Complex IV is promptly 
recovered upon decreasing the NO bioavailability. Under the conditions explored, 
that is, low NO concentration, the involvement of complex I, though possible, is 
less likely [131]. The analysis of the functional state of the respiratory chain 
complexes seems to confirm that, in the presence of melatonin, the inhibition is 
located at the level of complex IV.  
Synchronously with the down regulation of the respiratory chain, a partial 
decrease of ATPOXPHOS production is observed. The inhibition of ATPOXPHOS 
production is better observed in the absence of glucose, when the contribution of 
glycolysis is minimized. Under these conditions, the overall ATP level is almost 
halved, compared with cells maintained in glucose [411]; the addition of 
oligomycin causes a dramatic decrease of ATP, whose amplitude is indicative of 
the OXPHOS contribution to the overall ATP detected. The ATPOXPHOS produced 
by melatonin-treated cells is reproducibly smaller than in controls. The effect, 
though statistically significant, is small, likely due to an efficient glycolytic 
compensation. OXPHOS impairment and glycolytic compensation have been 
further substantiated measuring lactate [408]. The basal lactate, whose 
concentration is proportional to the ATPglycolitic, is higher in cells treated with 
melatonin. These results are in accordance with the literature data showing an up-
regulation of glycolytic enzymes in the rat pineal gland [425]. In the presence of 
OXPHOS inhibitors, the lactate production increases in both melatonin treated 
and untreated cells. This is due to glycolytic compensation to the overall ATP 
production. The difference between lactate produced in the presence and absence 
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of OXPHOS inhibitors is proportional to ATPOXPHOS, whose value is lower in 
cells treated with melatonin relying on glycolysis to a significant extent.  
Taken together, these findings suggest that nanomolar melatonin administered to 
intact HaCaT cells produces a transient but substantial rise of the constitutive 
nNOS, producing NO. The induced increase of NO leads to a reversible and 
partial inhibition of the respiratory chain with a decrease of mitochondrial ∆ψ and 
depression of OXPHOS. This leads, in turn, to a transient metabolic shift towards 
glycolysis. The mechanism through which low melatonin concentrations in the 
extracellular medium might induce the increase of nNOS expression is still 
unclear. It presumably involves a receptor-mediated melatonin signalling. Among 
keratinocytes, the HaCaT cell lines express the cell surface MT2-type receptor 
(isoform MT2b) and the nuclear receptors, that is, the retinoid orphan receptor 
(RORa) and the NQO2 flavoprotein, also known as the MT3 melatonin binding 
site [426-428]. It is tempting to speculate that a time and concentration-dependent 
feed-back controls the effects of melatonin on the nNOS and that the basis of this 
control might involve the melatonin-calmodulin interaction and signalling [429]. 
In this frame, when the extracellular hormone concentration is low (nanomolar or 
less), the nuclear mediated nNOS activation occurs, also sustained by the cell 
availability of calmodulin (high affinity nNOS cofactor [430]). As the incubation 
time increases, the intracellular concentration of melatonin (and/or its metabolites) 
proportionally increases; at this stage, due to the high affinity of melatonin for 
calmodulin [248] a competition of melatonin and nNOS both for calmodulin 
occurs, inducing progressive nNOS inhibition as the melatonin concentration rises 
[303] (Fig. 40). The existence of such equilibrium, if confirmed, would explain 
the results observed, also reconciling some discrepancies in the literature about 
the effects of melatonin, both on mitochondria and NOS. In conclusion melatonin 
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seems to act as a modulator of nNOS activity and consequently as a modulator of 
NO concentration in the cell.  
 
 
 
Fig. 40: Melatonin and the “keratinocyte hypothesis”. At pico-nanomalar concentration, melatonin 
induces a significant increase of nNOS overexpression presumably trough a melatonin-receptor-
mediated signaling. Under this condition, calmodulin can predominantly interact with nNOS, 
leading to production of NO and modulation of mitochondrial function. Upon increasing 
melatonin concentration (>1 nM) in the culture medium or its time of incubation, its intracellular 
concentration also rises: under these conditions, melatonin inactivates calmodulin (CaCaM) 
leading to nNOS inhibition (from Sarti et al., 2013).  
 
It has been previously reported in the literature that melatonin counteract the toxic 
effect of NO exerted when its level are highly increased. In this context,  
melatonin was proposed to act as a direct free radical scavenger of RONS, inhibits 
iNOS expression and seizes CaM to nNOS. In our experiments, however, we have 
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observed that melatonin is able to induce the nNOS expression, without leading to 
cell damage.  
The above consideration lead to the suggestion that melatonin seems to maintain 
the NO concentration level in a range compatible with a physiological and 
positive role, such as its function in the processes of learning and memory and in 
the regulation of mitochondrial respiration. All together these findings could give 
a contribution also concerning the role played by NO in the regulation of sleep-
wake cycle. This data are consistent with a physiological regulation of 
mitochondrial respiration and cell bioenergetics. 
Nevertheless a very different scenario may arise facing a pathological condition 
such as the Alzheimer‘s disease (AD). AD is a severe neurodegenerative disorder, 
characterized by a progressive loss of neurons and synapses particularly in brain 
region involved in learning and memory. The clinical hallmarks of AD are 
progressive impairment of memory, learning, judgment and decision making, 
eventually causing dementia in older people [312, 431].  
The key factor in these illness is the amyloid β-protein, also named Aβ-peptides or 
simply Aβ. The Aβ peptides are produced proteolytically by β- and γ-secretase 
acting on the β-amyloid precursor protein (APP). The Aβ-peptides are prone to 
aggregation in highly toxic oligomeric assemblies (Aβ-oligomers).  
Recently, the hypothesis that a mitochondrial dysfunction contributes significantly 
to pathogenesis and evolution of AD was formulated, supporting strong evidence 
that correlate AD to mitochondrial damage in brain cells. The molecular 
mechanism underlying the mitochondrial dysfunctions observed in AD is still 
mostly obscure and the question of a possible role for NO in this context suggests 
experimental investigation.  
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In this work, we used 7PA2 cells as a cellular model system of AD. 7PA2 cells 
are Chinese Hamster Ovary cell lines (CHO) that stably express the human APP 
isoform, 751 aminoacids in length (APP751) that contains the human Val717Phe 
(V717F) mutation associated with familial Alzheimer’s disease [432-434]. These 
cells are among the best characterized cellular models of Aβ production and 
oligomerisation [435].  
We have addressed the issue concerning the involvement of NO in the 
mitochondrial dysfunction in AD by comparing the nitrate and nitrate (NOx) 
accumulation in the supernatant of CHO (WT) and 7PA2 (mutated) cells. 
Interestingly, the NOx production is ~ 3 times higher in 7PA2 cells respect to 
CHO cells. This result suggests a possible bioenergetic impairment in 7PA2 cells 
and consistently with this finding we have also observed that the oxygen 
consumption and the mitochondrial membrane potential of 7PA2 cells are 
strongly impaired. The step by step analysis of the respiratory complexes activity 
shows a fairly uniform gradual depression of the functional activity of the 
respiratory chain in AD cells, though more evident at the level of complex I and 
complex IV. These results are in accordance with a recent study describing an 
impairment of complex I and complex IV activity induced by synthetic Aβ added 
in vitro [370]. Simultaneously 7PA2 cells display a lower (~ 20 %) stationary 
production of ATPOXPHOS. In addition, the 7PA2 cells seems to be less efficient 
than controls in compensating with glycolysis the olygomicin-induced OXPHOS 
impairment, as if the bioenergetic machinery of 7PA2 cells was less properly 
organized in both the oxidative and glycolytic metabolic compartments. Our 
findings suggest that the 7PA2 cells are bioenergetically less active than controls. 
Unfortunately, whether the mitochondrial impairment in AD is induced directly 
by NO or by Aβ remains uncertain. The Aβ peptides, also, in fact, have been 
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shown to directly interact with the respiratory complex IV [436] and respiratory 
complex I in vitro [437], and Aβ is detectable in mitochondria [345, 346]. 
Moreover, the interaction between the Aβ-peptides and membrane bilayers has 
been previously demonstrated [438]. The Aβ-peptides are able to deeply penetrate 
and perturb membrane structure, altering its viscosity and permeability properties, 
also contributing to formation of membrane pores [438]. In the case of 7PA2 
cells, the modification of the membrane structure could possibly contribute to the 
explanations of the observed lower respiratory capacity in these cells. It is also 
worth to consider that the accumulation of Aβ oligomers may produce sequential 
inflammatory and oxidative events [439-441]. The literature data are fully 
consistent with the higher ROS and NOx production herein detected in the 7PA2 
cells. Aβ plaques and Aβ oligomers are in the middle of a complex set of 
interaction among astrocytes, microglia and neurons originating a 
neuroinflammatory response [311] (Fig. 41). The over-activation of microglia 
induces the over-expression of pro-inflammatory cytokines and the consequent 
increase of iNOS expression (Fig. 41). The induction of iNOS in 
immunocompetent cells leads to NO production at µM (high) concentrations. 
These high levels of NO could lead to a persistent inhibition of the mitochondrial 
respiration, according to the PW2 inhibition mechanism [8]. Under these 
conditions, the mitochondrion produces an excess of O2- that reacts with NO to 
form highly reactive and toxic peroxinitrite (ONOO-), which in turn evokes 
oxidative stress and damage of proteins, lipids, and finally, mitochondrial 
dysfunction [78]. These circumstances induced by ONOO- overproduction lead to 
a pathological impairment of the cell bioenergetics. It is worth considering that 
oxidative stress and particularly ONOO- overproduction is significant in AD. 
Therefore, the high levels of NO are able to inhibit also Complex I. A constantly 
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increased NO bioavailability has been shown to induce the S-nitrosation of Cys-
39 on the ND3 subunit of Complex I, whose function becomes severely inhibited 
[131].  
 
↑ iNOS
↑ NO
Mitocondrial ∆Ψ ↓
Oxphos ↓
Aβ plaques
and Aβ oligomers
 
 
Fig. 41: Alzheimer’s disease and mitochondrial dysfunction hypothesis. Aβ contributes to induce 
neuroinflammation and oxidative stress in early event of AD. A chronic inflammation induces the 
iNOS expression in immunocompetent cells. The production of high NO levels could lead to a 
persistent inhibition of mitochondrial respiration, which occurs at the level not only of Complex 
IV but also of complex I. Under these conditions a mitochondrial dysfunction take place (modified 
from Rosales-Corral, 2012). 
 
In this frame, it is worth to keep in mind that our AD cellular model systems are 
actually ovary cells, not neurons. According to our results, the 7PA2 cells display 
a Warburg effect. Neurons, however, do not perform glycolysis, and a more 
severe bioenergetic impairment would be expected in the case of neuronal cells of 
AD patients, due to an intrinsically lower ability to compensate an OXPHOS loss 
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with glycolysis [57]. The impairment of OXPHOS in neurons of AD patients 
could certainly lead to more serious consequences such as cell death. Moreover, it 
was found that neuronal death during AD is associated with increased expression 
of iNOS and is partially reversed by selective inhibitors of this enzyme [442]. 
Because iNOS enhances the cellular NO concentration to a greater extent than 
eNOS or nNOS, it may be an important mediator of cytotoxicity in the brain [80, 
443]. Several authors showed a significant impairment of nNOS in the 
hippocampus of Aβ42 injected aged rats. The decrease of nNOS expression, 
induces loss of NO-dependent neuronal functions, such as memory and learning 
[78]. The same authors observed an increase of nNOS expression in the 
hippocampus of Aβ42 injected young rats. Under these conditions nNOS-derived 
NO seems to play a protective role against Aβ-induced damage, possibly by 
inducing an improvement in the learning and memory. In order to counterbalance 
insufficient tissue oxygenation in AD brain, the eNOS is activated. This can be a 
positive event in young patients where eNOS keeps blood vessels dilated and in 
this way NO favours a deeper tissue oxygenation. On the other hand in aged 
patients the blood vessels are less elastic and NO might fail to induce 
vasodilatation and brain oxygenation. If this was the case, the hypoxic condition 
would favor the NO-inhibition of CcOX, following PW2. All these observations 
indicate that a misbalance among the different isoforms of NOS occurs in AD, 
although still poorly understood [78]. In conclusion, based on the preliminary 
evidence shown in this work, we might conclude that nitric oxide plays a critical 
role in AD.  
Is it just a coincidence that while the probability of experiencing AD grows with 
age, melatonin declines? It has been shown that a cerebral spinal fluid (CSF) 
deficiency of melatonin precedes clinical symptoms of AD [444]. Moreover sleep 
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disruptions, nightly restlessness, sun downing and mood disorders are frequently 
observed in elderly and particularly in patients with AD [311, 445, 446]. These 
symptoms are related with decreased levels of both melatonin and melatonin 
receptors in AD patients [447, 448].  
A growing body of evidence supports the potential role of melatonin as an 
effective adjuvant in AD [449-454]. Melatonin is able to scavenge RONS 
including NO and ONOO-, is a potent antioxidant that inhibits also iNOS 
expression, modulates pro-inflammatory processes, may impair calcium-
dependent toxicity, prevents amyloid overproduction, mitochondrial damage and 
the apoptotic phenomena related with AD. Also relevant are the protective effects 
of melatonin on cognition in a variety of tasks of working memory, spatial 
reference learning and memory and basic mnemonic function, as observed in a 
transgenic model of AD [455]. It has been shown that MT2 receptor-deficient 
mice undergo impairment of synaptic plasticity and learning-dependent 
behaviour, suggesting that MT2 receptors participate in memory processes [456]. 
It is worth considering that HaCaT cells used in our experiments express the cell 
surface MT2 receptor and that according to our results nM melatonin induces an 
over-expression of nNOS in HaCaT cells. 
In conclusion, we think that our work may contribute to clarify on one side the 
melatonin induced effect of NO on mitochondria in a physiological circadian 
context, while on the other side a possible role of NO in AD. 
Considering that melatonin is capable of modulating NO bioavailability and cell 
bioenergetics, it would be interesting to investigate, therefore, in the future, 
whether, based on this novel function, melatonin might also have a role in the 
memory and learning processes altered in AD.  
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